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ABSTRACT 
 
 Metabolic syndrome (MetSyn) is the clustering of multiple metabolic disorders 
that further increase the risk for cardiovascular disease and has been recently linked to 
poor lymphatic function. The lymphatic system plays a crucial role in maintaining 
oncotic balance and returning excess fluid and macromolecules back to the blood 
circulation. In this dissertation we addressed the role of macrophage polarization and 
nitric oxide mechanisms in lymphatic dysfunction in a rat model of MetSyn. We 
hypothesized that mesenteric lymphatic vessel dysfunction would be associated with a 
polarization switch of resident macrophages after induction of peritonitis or metabolic 
syndrome. We used an intra-peritoneal injection of lipopolysaccharide (LPS) to simulate 
peritonitis in the rat and a seven-week high fructose-feeding regime to induce the 
MetSyn. We distinguished macrophage polarization and recruitment to the lymphatic 
collecting vessels using immunofluorescence and a combination of CD163, CD206, and 
major histocompatibility complex II (MHCII) expression. We determined the intrinsic 
mesenteric lymphatic contractility using the isolated mesenteric lymphatic vessel 
isobaric preparation. LPS-induced peritonitis increased the macrophage accumulation 
two fold and increased both CD163+CD206+ and CD163-CD206+ cell populations and 
had severely impaired lymphatic contractility. We also found evidence for a phenotype 
switch from CD163+MHCII- M2 macrophages to a M1 skewed CD163+MHCII+ 
phenotype in the MetSyn rats and impaired lymphatic contractility. Additionally, 
cultured lymphatic endothelial and muscle cells were found to express macrophage 
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maturation and expansion markers in response to LPS stimulation. We also examined 
the role of nitric oxide in the contractile regulation of lymphatic thoracic ducts isolated 
from MetSyn rats. We found a reduced flow-dependent inhibition of contractility in 
metabolic syndrome thoracic ducts despite a normal response to the exogenous nitric 
oxide donor S-nitro-N-acetylpenicillamine (SNAP). The reactive oxygen species 
scavenging agent 4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl (TEMPOL) did not 
restore flow sensitivity, however control vessels treated with the nitric oxide synthase 
inhibitor L-NG-nitro arginine methyl ester (LNAME) had comparable flow inhibition to 
MetSyn thoracic ducts. Western blots of thoracic ducts revealed a 60% reduction in the 
expression of eNOS, which can explain the loss of shear sensitivity. Thus, this study 
demonstrates the mechanisms that underlie lymphatic dysfunction in the MetSyn. 
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CHAPTER I  
INTRODUCTION * 
 
Rationale 
Obesity has reached epidemic proportions as it affects over one third of the 
United States population. Obesity is defined as having a body mass index ≥30 (237). 
Obesity predisposes the patient to other metabolic related disorders such as 
hypertension, diabetes, stroke, kidney disease, and cardiovascular disease (CVD) and 
accrues an estimated $147 billion in annual medical costs (1, 114, 115). Importantly, 
obesity appears to be the strongest link to the development of the metabolic syndrome, 
which is diagnosed when the patient fulfills at least 3 of the following 5 criteria: blood 
pressure over 130/85, fasting blood glucose >100mg/dl, serum triglycerides >150mg/dl, 
HDL cholesterol <40mg/dl, and abdominal obesity (40inches men, 35inches women) 
(114).  Patients that develop the metabolic syndrome are at a higher risk for developing 
fulminant type II diabetes mellitus (TIIDM), kidney failure, and are at greater risk for 
adverse cardiovascular events than the sum of the individual risk factors alone (175, 
199). Additionally, up to 85% of patients with TIIDM also fall under the metabolic 
syndrome spectrum (153). While the diagnosis was initially controversial, the metabolic 
syndrome is now readily accepted as a disease state with appreciated risks that have 
spread globally in parallel with obesity. The metabolic syndrome increases the risk of 
developing CVD by over three fold and the associated mortality of CVD increases up to 
five fold higher (175). Cardiovascular impairment is the leading cause of mortality from 
*Part of this chapter is reprinted with permission from “Impairments in the intrinsic contractility of mesenteric 
lymphatics in a rat model of metabolic syndrome” by Zawieja SD, Wang W, Nepiyushchikh Z, Zawieja DC, 
Muthuchamy M. 2012. Am J Physiol- Heart and Circulatory Physiology, 302, H643-H53, Copyright 2014 by The 
American Physiological Society. 
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the metabolic syndrome with dysfunction of both the micro- and macro-vessel blood 
vasculature and impaired heart function (21, 46, 69, 194, 294). However, little work has 
addressed the impact on the lymphatic vasculature and function that is critical to 
maintaining tissue fluid and macromolecule homeostasis, immunity, and the prevention 
and resolution of edema (38).  
Failure of lymphatic function results in chronic and progressive swelling termed 
lymphedema that can be the result of genetic abnormalities or vessel damage (256-258). 
Obesity is a historical risk factor for post-operative lymphedema in cancer patients (126, 
208). Additionally, obesity has been characterized as a mild edematous state with excess 
water retention and swelling, which suggests lymphatic insufficiency (23, 272). Yet little 
work has been completed to increase our understanding of the role lymphatic function in 
metabolic syndrome.  Many of these phenomena have been prescribed to venous 
insufficiency with little interest to lymphatic function despite the role lymphatic vessels 
play in maintaining fluid and macromolecule homeostasis in the tissue (225, 336). The 
link between obesity and lymphatic dysfunction has recently crystallized in the 
appearance of a previously rare medical condition called massive localized lymphedema 
(MLL) that affects up to 80% of morbidly obese patients (12, 18, 41, 81, 111, 144, 193, 
214). MLL has dramatically risen in occurrence with the rise of the morbidly obese 
population, which fit the diagnosis parameters for the metabolic syndrome (86, 87). 
Furthermore, genetic models of lymphatic disruption or direct physical ablation often 
result in expansion and hypertrophy of adipose tissue or fulminant obesity (13, 125, 208, 
349). Lymphatic vessels that drain adipose tissue also show reduced macromolecule 
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clearance in obese patients (9). This dissertation seeks to review the current literature 
regarding the links that exist between metabolic syndrome factors and lymphatic 
function, and provide the independent research carried out to further address this 
association. 
 
Hyperglycemia and the Insulin Resistant State in Metabolic Syndrome 
Circulating blood glucose concentration is maintained at approximately 5mM 
(90mg/dl) by the action of two different peptide hormones, insulin and glucagon. They 
are produced by beta cells and alpha cells, respectively, found in the islet of Langerhans 
of the pancreas. Insulin is released when blood glucose concentrations are high and 
promotes glucose uptake and inhibits gluconeogenesis, the endogenous production of 
glucose by the liver. In contrast, glucagon stimulates gluconeogenesis and is critical for 
preventing fasting blood glucose levels from dropping too low. The metabolic syndrome 
state is characterized as a chronic hyperinsulinemic and hyperglycemic state especially 
in the post-prandial, or fed, state (21). Glucose levels rise in the post-prandial state from 
nutritional absorption and transport to the blood through the portal circulation. Insulin 
stimulates glucose uptake through the translocation of glucose transporter 4 (Glut4) to 
the cellular membrane in skeletal muscle and adipose tissue, which are responsible for 
approximately 80% and 5% of post-prandial glucose uptake, respectively (64).  
Beta cells secrete insulin in response to an inhibition of adenosine triphosphate 
(ATP) sensitive potassium channels (KATP) as ATP builds up within the cell. These 
channels allow potassium ions to move down their concentration gradient out of the cell 
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and thus hyperpolarize the beta cell’s membrane, making membrane potential more 
negative (30, 44). As glucose in the blood rises, intracellular glucose metabolism 
concomitantly increases in the beta cell due to transport via glucose transporter 2 (Glut2) 
in rodents and Glut1 in humans (62). Metabolism of the influx of glucose increases the 
ATP concentration within the cell, which will block the efflux of potassium out of the 
cell through KATP channels (44). Cellular membrane potential increases with 
accumulation of potassium and it reaches a threshold that stimulates plasma membrane 
voltage gated calcium channels to allow calcium entry into the cell (44). Calcium influx 
regulates the fusion of vesicles to the plasma membrane and insulin is ultimately 
secreted.  
The metabolic syndrome is characterized as a chronic but mild inflammatory 
state that is propagated by over-nutrition and progressive insulin resistance. Insulin 
resistance is the decreased sensitivity of circulating insulin and requires a higher 
secretion of insulin to respond to a glucose challenge and explains why patients have 
both elevated insulin and glucose levels (24, 131, 134, 283, 297). Insulin resistance is 
mediated by a loss of insulin receptor substrate -1 (IRS-1) availability, or inhibition of 
insulin receptor autophosphorylation, or inhibition of phosphorylation (135, 136). The 
insulin receptor is a member of the receptor tyrosine kinase family that resides as a 
dimer on the plasma membrane and undergoes a conformational shift, and subsequently 
autophosphorylation, in response to binding insulin. Autophosphorylation of the insulin 
receptor complex results in the recruitment of the IRS-1 and IRS-2, which are 
themselves targets for phosphorylation. Ultimately, insulin will increase the 
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translocation of the glucose transporter Glut4 to the cell membrane and increase the 
internalization of glucose from the circulation. Disruption of this phosphorylation 
cascade prevents proper insulin signaling and glucose uptake by the skeletal muscle and 
adipose, which account for over 80% of the glucose removal in the post-prandial state 
and results in the post-prandial hyperglycemia in the metabolic syndrome (64). Insulin 
insensitivity also has a profound effect on the fasting blood sugar levels due to a loss of 
repression of the gluconeogenic action in the liver (117).  
Insulin signals primarily through the IRS-1-mediated activation of phospho-
inositide 3 kinase (PI3K) (117). PI3K converts the phosphatidylinositol (3,4)-
bisphosphate (PIP2) to phosphatidylinositol (3,4,5)-trisphosphate (PIP3) (117). Protein 
kinase B (PKB), also known as AKT, will bind to the membrane phospholipid PIP3 
resulting in its activation. Activation of AKT inhibits the tuberous sclerosis complex 1 
and 2 (TSC1/2) repression of the mammalian target of rapamycin complex 1(mTORC1), 
which is a critical positive regulator of cellular anabolic processes (117). Insulin also 
inhibits the gluconeogenic action of the liver and insulin resistance results in excessive 
gluconeogenesis. Glucose 6-phosphatase (G6p) is a critical enzyme in the gluconeogenic 
process that is under transcriptional control of the forkhead box protein O1, which is 
inhibited and targeted for destruction by active AKT. This has been linked with 
nonalcoholic fatty liver disease, liver steatosis, and hepatic over production of 
triglyceride rich low density or very low-density lipoproteins (149, 231, 247, 261, 302). 
  Physiological insulin resistance is part of the negative feedback mechanism to 
regulate nutrient uptake of the cell as a function of its nutrient state. S6 kinase is an 
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effector of the mTORC1 pathway and will negatively regulate IRS-1 through 
phosphorylation on serine residues. Conversely, cells that are “starved” or nutrient-
deficient will have high adenosine monophosphate to adenosine triphosphate levels 
(AMP/ATP) levels (33, 259). When cellular AMP rises, it activates the AMP kinase 
(AMPK) that opposes effects of AKT in regards to mTORC1 activation through 
activation of TSC1/2 (309). Pathophysiological insulin resistance can also be derived 
from cellular stress and inflammatory cytokine production (134). Liver insulin 
insensitivity has been linked with chronic sub-clinical inflammation, elevated fatty acid 
flux, and elevated expression C–reactive protein (CRP) (5, 68, 188, 231, 346). CRP is 
produced by hepatocytes in response to IL-6 stimulation of toll like receptor (TLR) 
activation, including activation by dietary endotoxin (96, 275, 290). Rodent models of 
metabolic syndrome have demonstrated a critical role for dietary endotoxin transport 
through the portal circulation in the pathogenesis of liver inflammation and damage in 
obesity and metabolic syndrome models (96, 157, 275, 290, 299, 325). CRP is a potent 
inflammatory molecule that is part of the acute phase response and has been linked with 
TIIDM, stroke, atherosclerosis, and insulin resistance in muscle and endothelial cells 
(236, 252, 347). Hepatocytes and liver macrophages, Kupffer cells, have an elevated 
production of IL-6 in models of obesity and metabolic syndrome (60, 78, 282). IL-6 
specifically activates expression of suppressor of cytokine signaling 3 (SOCS3), which 
acts to prevent the autophosphorylation of the insulin receptor and phosphorylation of 
the IRS-1, thereby contributing to insulin resistance (148, 162, 243). Tumor necrosis 
factor-α (TNFα) is another inflammatory cytokine that has potent insulin desensitizing 
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actions through inhibitory phosphorylation of IRS-1 at the serine residues (131). 
Inflammation within the adipose tissue is a large source of TNFα production in obesity 
and metabolic syndrome and exacerbates the insulin resistance in the adipose tissue 
(134, 135, 137).  
 
Obesity and Adipose Inflammation in the Metabolic Syndrome 
The strongest risk factor correlated with the development of metabolic syndrome 
is obesity and the expansion of adipose tissue, particularly the visceral fat in the 
abdominal cavity (114). Excess nutrient storage and adipose dysfunction are hallmarks 
of the metabolic syndrome and inflammatory state (19, 140, 341). Adipose tissue is 
primarily composed of adipocytes volumetrically, but is also host to fibroblast, pre-
adipocytes, innate and adaptive immune cells, and cells from the microvasculature. 
Adipocytes are the body’s main site of energy storage in the form of vesicles filled with 
triglycerides and cholesterol and play a key role in the regulation of satiety and energy 
flux (4).  
Adipocytes respond to insulin stimulation with glucose uptake through Glut4 
translocation and also fatty acid uptake through translocation of fatty acid transport 
protein 1 (FATP1) to the outer membrane (339). While the liver is the primary site of de 
novo lipogenesis, a modest amount occurs in the adipose tissue as well (71). However, 
the glucose uptake in response to insulin stimulation is primarily intended to provide the 
substrate for glyceroneogenesis. The adipocytes utilize glycerol for esterification of 
absorbed fatty acids into triglycerides that are stored in specialized vacuoles called lipid 
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droplets. Fatty acids can be absorbed basally by diffusion through the cell membrane but 
translocation of FATP1 to the membrane increases fatty acid capture and absorption. 
Cleavage of circulating triglycerides to glycerol and fatty acids is performed by 
lipoprotein lipase, which is also under regulation by insulin (289, 304). Peroxisome 
proliferator activated receptor gamma (PPARγ) and sterol regulatory element binding 
protein 1c (SREBP1c) are two critical regulators of fatty acid uptake and storage and 
adipocyte development that is positively regulated by insulin (333). PPARγ positively 
correlates with the expansion of the adipose tissue and the differentiation of the pre-
adipocytes into mature adipocytes (147, 313). However, therapeutic activation of PPARγ 
restores insulin sensitivity, reduces adipose inflammation, while further increasing fat 
expansion in the metabolic syndrome. SREBP1c expression is blunted in models of 
obesity and insulin resistance in the adipose tissue (273).  Reduction in the expression of 
adipocyte SREBP1c results in poor fatty acid uptake and storage in models of metabolic 
dysfunction (49, 168). Consistent oversaturation of nutrients to the storage capacity in 
regards to the underlying dysfunction in the adipocytes results in aberrant adipogenesis 
(lipomas), ectopic fatty acid uptake, and triglyceride accumulation in the liver and 
skeletal muscle (170, 172).  
Adipocytes also provide the necessary fatty acids for global cellular metabolism 
through a process of lipolysis that breaks down stored triglyceride and releases non-
esterified fatty acids.  Lipolysis is heavily regulated by insulin through its negative 
regulation of hormone sensitive lipase (209). Hormone sensitive lipase cleaves stored 
triglyceride into glycerol and fatty acids and is down-regulated in the metabolic 
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syndrome state (146, 181, 306). Adipocytes are also the primary source of the circulating 
peptide hormones leptin and adiponectin. Adiponectin is negatively associated with fat 
mass in contrast to leptin, which is positively correlated with fat mass and obesity (151, 
205). Adiponectin is a strong sensitizer of insulin signaling through its activation of 
AMPK and it is reduced substantially in metabolic syndrome and in the expansion of 
adipose tissue (150, 151, 205, 342). It can be secreted as a globular monomer that retains 
some signaling, but is secreted primarily as a homotrimer, multimers of trimers that have 
critical impacts on signaling (150, 190). The low molecular weight globular form is 
recognized by adiponectin receptor 1 (AdipoR1) and activates AMPK (150). Full-length 
adiponectin oligomers will activate peroxisome proliferator alpha (PPARα) via 
adiponectin receptor 2, but both receptors AdipoR1 and AdipoR2 utilize T-cadherin as a 
co-receptor (150, 345). AMPK and PPARα activation directly affect insulin sensitivity 
and fatty acid oxidation, pathways that are repressed in the metabolic syndrome state, 
partially due to the reduction in adiponectin levels(184). 
 Leptin, on the other hand, correlates strongly with body mass and expansion of 
the adipose tissue, and also is independently correlated with metabolic syndrome risk 
(95, 138). Leptin regulates satiety through its action in the hypothalamus, particularly 
within the arcuate nucleus. Its action is reduced in obesity and metabolic syndrome due 
to elevated expression of SOCS3 resulting in leptin resistance (22). SOCS3 inhibits the 
phosphorylation of signal transducer and activator of transcription 3, the primary 
downstream signaling molecule of the leptin receptor (22). In addition to its role in 
regulating satiety, leptin also has profound effects on the innate and adaptive arms of the 
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immune system (203). Macrophages exposed to leptin increase expression of 
inflammatory genes, such as IL-6, TNFα, and chemokine (C-C motif) ligand 2(CCL2) 
(98, 192).  Leptin also reduces the activation and proliferation of CD4+CD25+ T 
regulatory cells (Tregs) (61).  
IL-10 expression is lower in the lymph nodes and adipose tissue in obesity or 
metabolic syndrome models (185). IL-10 can inhibit T cell activation and also skew the 
macrophage polarization to the anti-inflammatory alternative activation state (M2). 
Lowered expression of IL-10 in the adipose tissue is also a characteristic of obesity and 
metabolic syndrome in conjunction with chronic but sub-clinical adipose inflammation 
(65, 141, 185). The adipose tissue is heavily invested with resident macrophages that 
help maintain adipose function through regulation of angiogenesis and production of 
anti-inflammatory markers (195, 196). Resident adipose tissue macrophages (ATMs) 
maintain an alternative activated phenotype (M2) that is characterized by the expression 
of macrophage mannose receptor (CD206), the scavenger protein CD163, and 
production of IL-10, transforming growth factor beta (TGFβ), and arginase (195). 
Maintenance of the M2 polarization is closely linked to the production of interleukin-4 
(IL-4) by Th2 CD4+ T cells, but more importantly from eosinophils that heavily invest 
normal adipose tissue as well (216, 235, 293, 337). Production of IL-4 in the adipose 
tissue is dramatically reduced in metabolic syndrome in association with a loss of 
eosinophils (293, 337). Loss of IL-4 stimulation is linked to increased adipocyte necrosis 
in response to nutrient overload cellular stress. Rodent models of metabolic syndrome 
are highly linked with an M1-skewed macrophage polarization and increased 
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accumulation of macrophages in the adipose tissue (42, 195, 196). While specific 
markers for the M1 phenotype vary by tissue bed and host species, the M1 phenotype is 
classically linked with elevated MHCII and inducible NOS (iNOS) expression as well as 
production of the inflammatory mediators IL-1β, IL-6, and TNFα (195, 196, 219). 
Reversal of adipose dysfunction is linked to resolution of the adipose inflammation and 
enhancement of the M2 polarization of ATMs (42). Chronic inflammatory stress also 
promotes even greater adipocyte death and turnover and results in disrupted 
adipogenesis by the pre-adipocyte population (286, 288). Long-term obesity models 
exhibit hyperplastic adipose tissue that has lost the majority of its original adipocyte pool 
and has been reconstituted by smaller adipocytes that have reduced function (76, 83). 
Elevated adipocyte death is a hallmark of overexpansion and excessive nutrient loading 
of adipocytes in obesity (42, 195). Excess nutrient storage in the adipocytes, however, 
drives adipocyte hypertrophy and then hyperplasia in response to the chronic nutrient 
influx (59).  
Dietary endotoxin, endoplasmic reticulum stress, and poor adipose circulation 
increase adipocyte death and turnover. Apoptotic adipocytes are then engulfed by 
inflammatory ATMs that form a characteristic crown-like structure due to the large 
hexagonal geometry of adipocytes compared to the macrophage attempting to engulf it 
(222, 332). Chronic inflammatory stress also increases lipolysis resulting in a slightly 
elevated local non-esterified fatty acid pool that further reduces insulin sensitivity and 
has been linked to inflammation through ceramide production or potentially through 
TLR4 activation (145, 271, 277). TLR4 is a pattern recognition receptor that recognizes 
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LPS and has been suggested to recognize fatty acids, particularly palmitic acid although 
this remains controversial (224, 277). Elevated palmitic acid is linked to de novo 
production of a potent inflammatory mediator, ceramide, through action of the serine 
palmitoyltransferase 1 (SPT1) (145, 271). Both TLR4 activation and ceramide synthesis 
have been documented in the metabolic syndrome and obesity models and contribute to 
the chronic inflammatory state and adipose dysfunction. Genetic ablation of TLR4 or 
TLR2 protects mice from the development of obesity and adipose inflammation when 
placed on a high fat diet (128, 277). Direct infusions of endotoxin have also been linked 
with the development of insulin resistance, further strengthening the link between 
macrophage activation and adipose function (35). These studies have raised the 
possibility for increased sensitivity and activation in response to elevated dietary 
endotoxin loads (37, 173). 
 
Dyslipidemia and Liver Dysfunction in the Metabolic Syndrome 
The liver is the primary regulatory site for circulating lipids and liver dysfunction 
in the metabolic syndrome closely resembles and is linked to nonalcoholic fatty liver 
disease and liver steatosis (31, 96, 170, 247, 261). These disease states are similarly 
characterized by elevated hepatic production of triglyceride-rich low-density or very 
low-density lipoproteins that can increase the risk for endothelial dysfunction, 
hypertension, atherosclerosis, and severe cardiovascular events like stroke and 
myocardial infarctions (32, 51, 107, 108). The hepatocytes are the primary functional 
cells in the liver that regulate lipogenesis, the conversion of glucose into fatty acids 
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through de novo lipogenesis. Additionally, they regulate the incorporation of fatty acids 
into triglycerides that are packed on to lipoprotein complexes that carry the lipid stores 
through the circulation for peripheral metabolism. This cycling process regulates the 
levels of low-density and high-density lipoproteins in the circulation.  
Insulin promotes de novo lipogenesis through increasing the expression of 
SREBP1c that regulates the expression of key enzymes such as acetyl-CoA carboxylase 
and pyruvate dehydrogenase (15, 93, 239). Pyruvate dehydrogenase activation is a 
regulatory step in the conversion of pyruvate into acetyl CoA, which is the building 
block for fatty acid synthesis. SREBP1c expression is positively regulated by insulin 
signaling through the IRS-1 subunit and activation of mTORC1 downstream of 
PI3K(180). Paradoxically, liver SREBP1c expression is up regulated in the insulin 
resistant state (167, 171, 229, 247) despite loss of SREBP1c expression in the adipose 
tissue (168).  
Poor adipocyte function increases the fatty acid load on the liver and constitutive 
action of SREBP1c increases fatty acid storage in the hepatocytes. In addition to obesity, 
uric acid is also strongly correlated with hepatic fat accumulation and liver dysfunction. 
The high fructose model of metabolic syndrome also has a critical role for uric acid in 
hepatic inflammation and stress in the development and maintenance of the metabolic 
syndrome state (246). Hepatic stress can be induced by ATP depletion from excess 
fructose consumption and phosphorylation by the hepatic fructokinase. AMP levels 
increase as fructose is rapidly phosphorylated yet AMPK activity is paradoxically 
reduced. This is due to the activation of AMP deaminase by fructose-1-phosphate, which 
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initiates the catabolism of AMP into uric acid (176, 197). Uric acid directly inhibits 
AMPK function and stimulates a lipogenic profile in the hepatocyte by inducing 
mitochondrial stress and releasing excess citrate into the cytosol for fatty acid synthesis 
(40, 177). Circulating uric acid is also associated with the metabolic syndrome (154) 
through up regulation of CRP in the endothelial and muscle cells of the blood 
vasculature (154, 296). CRP expression has also been linked to dietary and portal 
endotoxemia and the activation of TLRs is a significant element in liver dysfunction in 
metabolic syndrome (213, 253, 291, 343). The majority of the dietary endotoxin is 
linked with the absorption of dietary fat and the formation of the chylomicrons within 
the enterocytes that line the intestine (105). Once the chylomicron is transported to the 
interstitial space, dietary endotoxin can disseminate through the lymphatic system, or the 
endotoxin can disassociate from the chylomicron and enter the portal circulation (105). 
Once in the liver it can activate the TLRs on Kupffer cells and hepatocytes, resulting in 
CRP, IL-6, and IL-1β signaling and inflammation (96, 253, 290, 300).  
Little is known of the fate of chylomicron-bound LPS as it traverses the 
lymphatic system but lymphatic endothelial cells express multiple functional TLRs and 
high fat meals are associated with node inflammation (79, 198). The inflammation 
associated with dietary endotoxin is progressive with over-nutrition as insulin resistance 
in the intestine is linked with overproduction of apolipoprotein B (apoB) and increased 
gut permeability to endotoxins (35, 36, 77, 84).  The enterocytes are the specialized 
epithelial cells that line the intestine and are the site of dietary fat absorption.  Insulin 
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resistance in the enterocyte increases the production of the atherogenic apoB48 
molecules that are correlated with elevated SREBP1c expression (77, 84, 119).  
 
Hypertension and Endothelial Dysfunction in the Metabolic Syndrome 
Hypertension in the metabolic syndrome state is linked to insulin resistance and 
blood vascular endothelial cell dysfunction (21, 46, 122). Vascular endothelial cells 
integrate multiple different signals, such as tissue metabolic demand, hormonal control, 
neural regulation, and mechanic forces to regulate blood flow through constriction and 
dilation of blood vessels in the periphery. Endothelial dysfunction is characterized by the 
insufficient production of dilatory mediators, specifically NO, which results in poor 
peripheral circulation and elevated blood pressure.  
Insulin is a potent vasodilator as stimulation of the PI3K-AKT pathway results in 
phosphorylation of eNOS at a critical serine residue that regulates its activity (217). 
AKT also integrates signals from mechanical stress such as shear stress to activate NO 
production (70).  Insulin also contributes to the maintenance of endothelial function by 
stimulating endothelial NOS (eNOS) expression and transcription, and arginosuccinate 
synthase, which is the rate-limiting step for arginine synthesis from citrulline (338). The 
function of eNOS is tightly regulated by phosphorylation, intracellular calcium, and 
availability of the substrate L-arginine (338). Proper eNOS activation also requires the 
presence of 5 required cofactors: tetrahydrobiopterin (BH4), heme, flavin 
mononucleotide, flavin adenine dinucleotide, and calmodulin.  
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NO is able to freely diffuse through the endothelial cell layer and induces 
relaxation in the smooth muscle cells. Soluble guanylate cyclase is found in the 
cytoplasm of the vascular smooth muscle cells and is activated by NO to increase cyclic 
guanosine monophosphate (cGMP) production (8, 94). This cGMP regulates the activity 
of protein kinase G (PKG) that, along with protein kinase A (PKA), is the major 
regulator for smooth muscle relaxation. There are two genes that produce PKG with 
PKG1 expressed in vascular smooth muscle in two isoforms (PKG1α and PKG1β). PKG 
mediates its vasorelaxation mechanisms through activation of KATP channels, activation 
of the RhoA associated kinase (ROCK) pathway, and inhibition of the inositol-3 
phosphate pathway. Activation of the KATP channels hyperpolarizes the cell membrane 
potential and prevents action potential generation in the pacemaker cells in the vessel 
wall, inhibiting contraction frequency. PKG also can inhibit contraction through the 
inactivation of myosin light chain phosphatase (MLCP). The inhibition of the MLCP is 
mediated by phosphorylation of the myosin phosphatase target subunit 1 by 
RhoA/ROCK activation. The cGMP can also indirectly activate PKA through inhibition 
of phosphodiesterases that target cAMP for degradation, and competition of 
phosphodiesterase activity, or direct activation of PKA (189, 206, 348). PKA will also 
activate potassium channels and contribute to the hyperpolarization, and both PKA and 
PKG activation regulate lymphatic muscle relaxation (223, 260, 323).  
In addition to the direct role of insulin in vasodilation, hyperglycemia is also 
negatively associated with poor vasodilation (29, 132, 280). BH4 is a critical cofactor for 
the production of NO, which regulates vasodilation, and is sensitive to the redox status 
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of the cell. Chronic elevations in circulating glucose increase its use as a metabolic 
substrate and result in high mitochondrial potential and elevated production of reactive 
oxygen species (ROS). BH4 production is linked to the activity of the rate-limiting 
enzyme GTP cyclohydrolase 1 (GTPCH1) and is critical in maintaining eNOS fidelity 
and function (39, 338). Oxidation of BH4 results in the complex of BH2 with eNOS and 
uncoupling of NO production in favor of superoxide (178). Superoxide itself is a potent 
ROS that can combine with NO to produce peroxynitrite, thus further lowering the 
bioavailability of NO. Peroxynitrite can oxidize BH4 into BH2, perpetuating the 
oxidative stress and reducing NO production (39, 338). Lowering mitochondrial 
potential or increasing the levels of BH4 through GTPCH1 expression normalize eNOS 
function and vasodilator capacity (52).  
The pro-inflammatory CRP molecule also inhibits NO production (230, 285). As 
previously described, CRP is elevated in the metabolic syndrome through production by 
the liver and in the endothelial and smooth muscle cells of the vasculature. Uric acid has 
been directly linked with the production of CRP in endothelial cells and contributes to 
the uncoupling of eNOS through activation of the nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase and down-regulation of eNOS and GTPCH1 (230, 285). 
 
Lymphatic Vasculature and Contractile Regulation 
The lymphatic vasculature is the nexus of tissue fluid and protein homeostasis 
and antigenic detection of self and non-self molecules (351). The goal of the lymphatic 
system is to collect and transport lymph, the collected interstitial fluid and metabolites or 
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products of cellular processes, for return to the blood circulation. Without reabsorption 
of macromolecules the oncotic pressure of the tissue would increase leading to excessive 
fluid extravasation and edema. Often times this process must go against a net pressure 
gradient, particularly in humans where fluid must travel against a gravitational gradient 
to return to the blood circulation due to our upright posture (351). This is accomplished 
through the action of both extrinsic and intrinsic forces that regulate lymph transport. 
Extrinsic forces include interstitial pressure and tissue compression, such as in 
gastrointestinal, cardiac, or skeletal muscle contractions that affect lymphatic transport 
(352). The compression of tissues plays a significant role in formation of lymph by 
temporarily forming a positive force for fluid to enter the initial lymphatic network.     
The initial lymphatics are blinded capillaries that are dispersed in the tissue and 
are characterized by an endothelial layer with a discontinuous basal lamina that are 
anchored to the extracellular matrix (43, 183). The surrounding tissue space expands 
with increased interstitial pressure and opens the highly permeable lymphatic endothelial 
capillaries (43). Primary lymphatic endothelial junctions have been characterized as 
button like structures with intermittent tight and adherens junctions that that allow 
interstitial fluid to pass through the inter-junction space (183, 344). The initial lymphatic 
network is characterized as a plexus that eventually feeds into larger vessels, although 
pressure gradients do not favor passive flow and unidirectional valves prevent backflow 
(17, 121, 212, 352). As the initial lymphatics coalesce into larger vessels, the basal 
membrane is less discontinuous and the first unidirectional valves can be observed, 
although these vessels lack significant muscle investiture or contractile function. These 
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vessels are described as “lymphatic pre-collectors” and feed into larger muscularized 
lymphatic collecting vessels. The lymphatic muscle cells in the collecting vessels 
provide the intrinsic force to propel lymph through the lymph nodes and eventually 
return it to the bloodstream. The lymphatic collecting vessels are circumferentially 
covered with unique muscle cells that display both the contractile machinery of cardiac 
and classical smooth muscle and have a complete basal lamina and zipper-like 
endothelial junctions (121, 212, 226, 344). The lymphatic system in mammals does not 
have a singular pumping mechanism such as the heart in the blood vasculature (352). 
Instead, the lymphatic collecting vessels are able to contract both tonically and 
phasically in coordination to regulate lymph propulsion (101, 248). This intrinsic lymph 
pump function is critical to global lymphatic function, but especially lymphatic vessels 
that drain non-compressing tissue beds or organs. Additionally, the number of valves 
increases in the collecting vessels demarcating a functional lymphatic unit called a 
lymphangion. The lymphangion is the smallest contractile unit that describes a valve 
region and the contracting segments upstream and downstream of it (212). Lymph is 
propelled from lymphangion to lymphangion using the pressure gradient generated by 
phasic contractions that are coordinated through both electrical and mechanical 
stimulation (54, 56, 57, 100, 121). Lymphatic muscle cells within a lymphangion are 
connected through gap junctions that allow electrical depolarization of the lymphatic 
muscle by the pacemaker cell to propagate and coordinate the vessel contraction (179, 
207, 238, 307, 316). Adjacent lymphangions do not contract simultaneously but appear 
to contract in succession (354). The upstream contraction cycle will increase the stretch 
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and filling of the adjacent downstream lymphangion, while simultaneously closing its 
unidirectional lymphatic valve in response to the intra-lymphatic pressure from 
contraction (354). These periods of systole and diastole have parameters similar to those 
in cardiac contraction cycles and these parameters are utilized to assess lymphatic pump 
function.  
The lymphatic pump is driven by the electrical depolarization of a pacemaker 
cell that has yet to be specifically identified but is located in the smooth muscle layer 
(179, 238, 307). Additionally, lymph transport can also be impeded by phasic 
contractions if pressure gradients favor passive lymph flow and lymphatic vessels must 
be able to regulate conduit function similar to the tonic constrictions and dilations 
observed in blood vessels (26, 100, 102, 104). Phasic contractions increase vessel 
resistance as a function of its diameter and potentially closure of the valve. Flow-
mediated shear stress plays a significant role in the inhibition of the phasic contraction 
frequency (chronotropy), contraction strength (ionotropy), and regulates vessel diameter 
through vessel tone modulation, primarily through NO production by the endothelium 
(26, 100, 102-104, 317).  
Proper lymph flow requires both the ability to generate force to propel lymph and 
to reduce resistance to lymph flow and lymphatics vessels from different tissues differ in 
their regulation of these processes (101). MLVs isolated from rats display a maximal 
contractility at a preload of 5cmH2O while the larger thoracic ducts display maximal 
pump activity at a preload of 3cmH2O (100, 101). Shear sensitivity in the thoracic duct is 
also much more sensitive to Flow-mediated lymph pump inhibition (100, 101). 
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Mechanisms of Lymphatic Contractility 
Lymphatic vessels must be able to regulate vessel pumping and resistance for 
proper lymph flow (17, 100, 102, 248). The duality of their function is reflected in the 
observation that lymphatic muscle cells express both cardiac and smooth muscle 
contraction machinery (226, 228). Smooth muscle tonic contraction and myogenic 
response is ultimately linked to intracellular calcium levels that are regulated by stretch-
activated calcium channels and calcium sensitivity (359). Transmembrane calcium flux, 
through voltage operated calcium channels, regulates the myogenic response to pressure 
through phosphorylation of the myosin regulatory light chain 20 (MLC20) subunits of the 
myosin complex (270). Phosphorylation of serine 19 of the MLC20 results in smooth 
muscle force production and tonic constriction in the lymphatic collecting vessels (326). 
Phosphorylation of the regulatory site is balanced by myosin light chain kinase (MLCK) 
and MLCP (129, 130). Myosin-actin interaction is regulated by intracellular calcium that 
interacts with calmodulin to activate MLCK. Activation of protein kinase C (PKC) will 
increase the sensitivity of the smooth muscle to calcium (331) through the 
phosphorylation of CPI-17 that can then strongly inhibit MLCP activity (80, 163). PKC 
also sensitizes force production to calcium concentration in skinned lymphatic vessels, 
suggesting a role in the amplitude of lymphatic phasic contractions (73, 74). Contraction 
strength in smooth muscle is also regulated independently of calcium through ROCK 
activity. ROCK activation will increase phosphorylation of the inhibitory subunit of the 
MLCP complex, myosin phosphatase target subunit 1 (MYPT1), further increasing the 
MLCP/MLC ratio. Both the regulation of MLC20 through MLCK and MLCP has been 
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implicated in the tonic constriction and myogenic response in lymphatic vessel function 
(133, 326).  
The lymphatic tissue also expresses molecular machinery found in cardiac tissue 
such as the cardiac actin and beta-myosin heavy chain. Cardiac muscle contractions are 
dependent on membrane depolarization and calcium induced calcium release from the 
sarcoplasmic reticulum (20).Calcium influx through voltage gated calcium L and T type 
channels opens sarcoplasmic reticulum (SR) stores, which further increases intracellular 
calcium to regulate both cardiac and lymphatic contraction amplitude. Cardiac muscle 
contractility is regulated by thin filament associated troponin-tropomyosin interaction 
(227). Calcium binds to the troponin complex, which causes a conformational shift in the 
tropomyosin complex and allows actin myosin cross bridging. Thus cardiac contractions 
are tightly regulated by excitation and calcium induced calcium store release (318). As 
in cardiac tissue, lymphatic muscle cells have a spike of calcium that precedes the phasic 
contraction (318). Lymphatic SR calcium release, both ryanodine- and IP3- sensitive, is 
linked to the lymphatic contraction amplitude (320). Studies from rat and guinea pig 
mesentery suggest that calcium spikes signifying pacemaker activation regulate 
chronotropy, but that basal calcium increases in lymphatic muscle over time in response 
to elevated pressure and may contribute to the myogenic tone activation observed over 
time as well (14, 54). Flow-mediated inhibition of lymphatic contraction frequency is 
mediated through both PKG- and PKA-mediated KATP channel activation in response to 
NO production (103, 104, 317, 321).  
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Inflammation and Lymphatic Dysfunction in the Metabolic Syndrome 
Lymphedema is the hallmark of severe lymphatic dysfunction and is a chronic 
and debilitating disease. Lymphedema can be caused by a genetic (primary) abnormality 
or by lymphatic vessel damage or dysfunction (secondary). Secondary lymphedema is 
seen with cancer patients that have lymph node removal and radiation (254, 256). 
Obesity has been historically linked with risk for developing post-operative lymphedema 
following a mastectomy (2, 126, 166). Even moderate obesity is associated with 
increased water retention and mild edema (324). The rise in obesity has increased the 
number of lymphedema cases due to the expansion of the morbidly obese population and 
crystalized the connection between lymphatic dysfunction and the metabolic syndrome 
state. Up to 80% of morbidly obese patients were found likely to develop severe 
swelling in the form of lymphedema at some point in their life (86, 87). Lymphedema is 
a chronic progressive disease that results from obstruction or dysfunction within the 
lymphatic vasculature. Originally misdiagnosed as angiosarcomas, morbidly obese 
patients will likely develop lymphedema, characterized as massive localized 
lymphedema (MLL), at one point in their life, despite the majority of patients with 
lymphedema displaying normal lymphoscintigraphy results, suggesting there was no 
genetic defect or obstruction in their lymphatic network (310). MLL is predominantly 
unilateral with a slight preference for female patients (55%female and 45% male) (41). 
This disease was commonly misdiagnosed due to its low occurrence rate and its 
predisposing factor of morbid obesity.  
  
24 
Over 34% of Americans are obese and, of those, over 6% were classified as 
severe (BMI>40) or morbidly obese (BMI>50), putting them at risk for developing 
MLL. MLL is linked to the nutritional and metabolic state of the patient, as recurrence of 
MLL after surgical removal of the afflicted tissue bed is common and weight loss and 
exercise programs appear to be beneficial in its prevention (85). Macromolecule 
clearance is reduced in a rodent model of obesity and many of these models fit 
parameters for the metabolic syndrome (9). The lymphatic system has historically been 
linked to adipose tissue, as lymphatic vessels are often surrounded by perivascular 
adipose throughout the body and lymph itself has pro-adipogenic properties (123, 125). 
The Prospero homeobox protein 1 (Prox-1) haplotype mouse model displays poor 
lymphatic vessel integrity, and the surviving mice develop adult onset obesity (125). 
Patients with severe diabetes also have elevated lymphangiogenesis in their skin and the 
endothelial cells are characterized by excessive inflammatory gene expression (118). 
One of the critical roles of the lymphatic system is to return tissue antigens both self and 
non-self to the node for proper immune surveillance in the lymph node. Failures of the 
lymphatic system delay the appropriate immune response and can cause further damage 
and inflammation in even sterile injury.  
Obesity has been described as a mild edematous state with chronic subclinical 
inflammation, and an increased risk of bacterial infections that can be explained in part 
by lymphatic insufficiency (139, 187). Models of inflammation in the peritoneum and 
intestine have demonstrated impaired lymphatic function in regards to vessel 
permeability and pump function (48, 204, 340). It is likely that similar inflammatory 
  
25 
mediators present in the metabolic syndrome state are responsible for the development 
of MLL and the risk associated with obesity in the development of post-operative 
lymphedema (254, 255). Intriguingly, secondary lymphedema is not always bilateral, 
suggesting that severe lymphatic dysfunction can be regionally regulated and suggesting 
a role for inflammation in the draining tissue. The lymphatic system production of 
dendritic cell chemoattractant factors and the transport of dendritic cells to the draining 
node have been heavily studied and are impaired in obesity (249, 250, 330). However, 
aside from the context of lymphangiogenesis, there is little information on the role of 
resident tissue macrophages and their interactions with the lymphatic system (159).  
Resident tissue macrophages are found throughout the body and play critical 
roles in maintaining tissue function and homeostasis in addition to their immunological 
roles. (106). In that aspect they share a similar function as the lymphatic system that 
drains these organ beds and recent work has begun to suggest a more active role for the 
lymphatic endothelium in the response and resolution of inflammation. As discussed 
earlier, the metabolic syndrome is associated with an altered macrophage phenotype in 
the primary adipose depots, and these macrophages have poor lymphatic clearance of 
macromolecules. Our lab has previously shown that MLV contractility (Figure 1) is 
impaired in a high fructose model of metabolic syndrome that is independent of gross 
obesity (357).  
The high fructose fed Sprague Dawley rat is a common and accepted model of 
metabolic syndrome due to the presence of both insulin resistance and gross 
dyslipidemia despite the lack of overt obesity. However, there was significant expansion 
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Figure 1. Impairment in the mesenteric lymphatic pump of a high fructose fed rat model 
of metabolic syndrome. Mesenteric vessels had significantly reduced intrinsic lymph 
pump flow at each pressure tested. This was significantly affected by reduced 
chronotropy of phasic contractions. MetSyn-metabolic syndrome * Denotes statistical 
difference at p<0.05. (357) 
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of the perivascular adipose tissue where the MLVs reside (Figure 2) (357). We 
confirmed that our 7-week feeding regime resulted in the metabolic syndrome state 
through elevated fasting insulin and triglyceride in addition to liver lipid disruption 
(Table 1) (357). This suggests that the chronic inflammatory environment in the 
metabolic syndrome is able to induce lymphatic dysfunction and may suggest that 
lymphatic contractility impairment contributes to the obesity-related lymphedema risk 
and massive localized lymphedema. Others have replicated these results using mouse 
models of metabolic syndrome (25, 330), although many questions remain. It is clear 
that inflammatory states are directly linked to lymphatic dysfunction but that poor 
lymphatic function can also contribute to or exacerbate that inflammation (350).  
 
The Specific Aims of this Dissertation  
1. To elucidate the association between macrophage polarization and the intrinsic 
lymphatic pump under conditions of inflammation and the metabolic syndrome. 
We examined the accumulation and polarization of macrophages and their spatial 
and temporal association with the vessels in the metabolic syndrome and an acute 
model of peritonitis. We then assessed the MLV contractility in response to 
stretch and the therapeutic potential of the anti-diabetic drug glibenclamide to 
restore MLV function. 
2. To determine the mechanisms of dysfunction of a conduit vessel, thoracic duct, 
in metabolic syndrome. We examined the sensitivity to flow-mediated pump 
inhibition and vessel resistance to imposed flow. We tested the sensitivity of 
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thoracic ducts isolated from metabolic syndrome rats to the exogenous NO donor 
S-nitro-N-acetylpenicillamine (SNAP) and the NOS inhibitor L-NG-nitro 
arginine methyl ester (LNAME). We also examined the role of endogenous 
production of ROS in thoracic duct regulation with the ROS scavenger 4-
hydroxy-TEMPO (TEMPOL).   
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Figure 2. Seven weeks of high fructose feeding increases the perivascular adipose 
accumulation in the Sprague Dawley rat. Perivascular adipose in the mesentery of 
control rats fed normal chow for 7 weeks A, B. Perivascular adipose area increased by 
over 20% in the fructose-fed rats C, D. (357) 
  
A B 
C D 
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Table 1. Parameters of the high fructose feed induction of the Metabolic Syndrome 
The high fructose model of metabolic syndrome does not cause significant weight gain 
compared to control chow-fed rats. Circulating insulin concentrations and triglycerides 
significantly increase in the fasting state in the high fructose fed rat model of metabolic 
syndrome. (357)  
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CHAPTER II 
LYMPHATIC VESSEL-ASSOCIATED MACROPHAGES MATCH TISSUE 
RESIDENT PHENOTYPES AND ARE ASSOCIATED WITH IMPAIRMENT 
OF THE LYMPHATIC PUMP IN THE METABOLIC SYNDROME 
 
Overview 
 The intrinsic lymphatic pump is critical to proper lymphatic function, the 
prevention of edema, and antigen presenting cell migration. The sub-clinical chronic 
inflammation observed in the metabolic syndrome (MetSyn) is both a symptom and 
driver of the disease state and is correlated with dietary endotoxin and macrophage 
inflammatory status. We have addressed the role of macrophage recruitment and 
investiture in the MLVs in response to both acute and chronic inflammation. We have 
utilized a LPS-induced peritonitis rat model and a seven-week high fructose fed rat 
model of MetSyn to address the association of macrophages and their polarization in 
lymphatic dysfunction. We found significant, yet different, alterations in macrophage 
polarization and investiture in response to both LPS-induced peritonitis and MetSyn. 
LPS-injected rats showed a two-fold increase in macrophage investiture in the 
perivascular adipose tissue and along the lymphatic vessel. The majority of macrophages 
maintained an M2 phenotype that was characterized as CD163+CD206+MHCII- and 
heavily invested along the lymphatic vessels. We also observed a dramatic increase in 
the presence of CD163-CD206+ macrophages within the vicinity of the lymphatic vessel 
that are not commonly observed in control rats. In contrast, MetSyn resulted in a M1-
  
32 
skewed macrophage population as observed by an increase in the number of positive 
CD163+MHCII+ macrophages in the tissue and residing on the lymphatic vessel. 
Cultured lymphatic endothelial cells expressed high levels of chemokine (C-C motif) 
ligand 2(CCL2), and monocyte colony stimulating factor (MCSF) basally and in 
response to LPS stimulation. Both lymphatic muscle and endothelial cells significantly 
increase granulocyte/monocyte colony stimulating factor (GMCSF) expression in 
response to LPS stimulation. Significant impairment in MLV contractility was observed 
in both LPS and MetSyn models, which was primarily regulated by reduced 
chronotropy. Therapeutic levels (1µM) of the KATP channel blocker glibenclamide (Glib) 
did not significantly improve contraction frequency or lymph pump function in isolated 
MLVs in MetSyn. Maximal activation of lymphatic vessels with high dose (10µM) Glib 
also failed to consistently increase lymph pump flow despite an increase in contraction 
frequency. These data demonstrate that inflammatory conditions, such as LPS or 
MetSyn, promote macrophage polarization in the mesenteric tissue and on the lymphatic 
vessel that is correlated to the lymphatic dysfunction in these two models, suggesting 
crosstalk between the statuses of macrophages and lymphatic function. 
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Introduction 
Obesity and its related metabolic diseases affect approximately 34% of 
Americans and is the strongest predictor of the MetSyn (114). Additionally, 
approximately 85% of the patients with type II diabetes (TIIDM) also fall under the 
conditions for diagnosis of MetSyn (153). The MetSyn increases the risk for 
cardiovascular disease greater than the sum of the parts. Patients are diagnosed with the 
MetSyn if they have 3 or more of the following: systolic blood pressure >135mmHg, 
high waist circumference (>40in male, >35in  female), hypertriglyceridemia  
(>150mg/dl), hyperglycemia (>100mg/dl fasting glucose), and low high-density 
lipoprotein (<40mg/dl male, <35mg/dl female) (115). The MetSyn state is also 
characterized by elevated ROS, insulin resistance, adipose inflammation, and chronic but 
subclinical-inflammation (1, 99, 114, 195, 341).  
Recent studies demonstrated a critical role for adipose tissue macrophage 
polarization in the pathogenesis of MetSyn. Induction of MetSyn is accompanied by 
increased production of inflammatory cytokines such as tumor necrosis factor alpha 
(TNFα), interleukin 6 (IL-6), and chemokine (C-C motif) ligand 2(CCL2) (42). The 
expression of these inflammatory cytokines is directly linked to the increased infiltration 
of macrophages and the classical (M1) polarization phenotype (195, 196). Under 
physiological conditions, adipose tissue macrophages demonstrate an alternative 
activated phenotype (M2) due to the expression of interleukin 4 by eosinophils (337). 
M2 macrophages produce the anti-inflammatory molecule interleukin 10 (IL-10), tumor 
growth factor β (TGFβ), and the interleukin 1 decoy receptor (219). Obesity reduces the 
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eosinophil population while simultaneously increasing the type 1 helper (Th1) CD4+ 
effector T cell production of interferon-γ (IFNγ) (219). IFNγ is the classical stimulator of 
the M1 phenotype, but recent studies have also suggested that macrophage polarization 
is driven by the ratio of MCSF and GMCSF (91, 143, 174). Exposure of monocytes to 
MCSF alone results in a typical anti-inflammatory M2 polarization while GMCSF can 
drive the inflammatory M1 phenotype. 
Obesity and TIIDM are both associated with microvascular dysfunction (2, 201, 
215, 266, 324). However, much of the focus on the peripheral edema associated with 
obesity has been decidedly on venous insufficiency (251, 308) with little regard to 
lymphatic function that we know is critical to fluid homeostasis (63, 254, 310). Obesity 
is also a historical risk factor for developing secondary lymphedema after a mastectomy 
and macromolecular clearance from the adipose is reduced in obese models (2, 67, 244).  
The association between lymphatic dysfunction and obesity becomes clear in the 
morbidly obese population (10, 81, 112, 144, 160, 214) that represent at least 30% of all 
secondary lymphedema cases (86). The phenomena known as massive localized 
lymphedema (MLL) has increased with the rise in the obese and morbidly obese (BMI 
>50) populations (85, 87). Surgical opportunities provide relief but there is a potential of 
relapse if the underlying metabolic dysfunction is not addressed (85). A recent study 
demonstrated that human TIIDM patients have elevated lymphangiogenesis in their skin, 
and their lymphatic endothelial cells express a prominent inflammatory profile (118). 
Macromolecule clearance by the lymphatics is also reduced in obesity (9) and likely 
contributes to the mildly edematous state (324). Finally, lymphatic dysfunction in Prox-1 
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haplotypes may lead to adult onset obesity in mice (125). The lymphatic system’s close 
association with adipose tissue underlies the connection between lymphedema, 
lipidemia, and adipose tissue function (124, 329).  
Proper lymphatic function is critical to tissue fluid and macromolecule 
homeostasis and antigen delivery to the node. Lymph is comprised of the interstitial 
fluid, cellular metabolites, and secretions that are taken into the lymphatic vessels and 
transported back to the bloodstream passing through multiple nodes in the process. 
Failure of the lymphatic system results in a chronic and progressive disease called 
lymphedema that can arise from genetic complications (primary) and vessel damage or 
dysfunction (secondary) (254, 256). This transport of lymph is against net pressure 
gradient and the intrinsic lymphatic pump and unidirectional valves are critical to this 
process as well as the prevention of edema (17). The muscularized lymphatic collecting 
vessels can be described as a series of lymphangions comprised of a lymphatic valve and 
the contracting segments both up- and downstream that act coordinately to generate 
temporary pressure gradients to propel lymph (212, 352, 354). This intrinsic lymph 
pump is regulated by the activation of pacemaker cells found within the vessel wall that 
depolarize frequently and generate the phasic contractions (212, 320). The pacemaker is 
highly sensitive to transmural pressure fluctuations and increases the firing frequency 
(chronotropy) with a maximal activation achieved around a transmural pressure of 
5cmH2O in the MLV (100, 101). Depolarization of the pacemaker drives the 
depolarization of the lymphatic muscle cell layer and activates calcium influx through L-
type channels (318). Calcium influx activates the SR release of calcium through both 
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ryanodine receptors and inositol-3-phosphate receptors (316). The calcium induced 
calcium releases by the SR and the calcium store management regulates contraction 
amplitude (316, 352). PKC has been shown to increase the sensitivity of lymphatic 
muscle to calcium and increase force production (74). 
Lymphatic vessels are also self-regulating through the generation of NO in 
response to the shear stress of lymph propulsion (26, 104). Shear-induced NO will 
activate both PKA and PKG in the smooth muscle that increases adenosine triphosphate 
(ATP) sensitive potassium channel (KATP) channel activity, hyperpolarizing the 
pacemaker and reducing the contraction frequency (102, 323). Glib is an anti-diabetic 
drug that increases the insulin release due to increased depolarization of the beta cells in 
the pancreas by inhibiting KATP channels. Glib also has been documented to restore 
lymphatic chronotropy  and function in the guinea pig model of ileitis and could 
potentially restore  lymphatic function in the MetSyn (315). Zucker Diabetic Fatty 
(ZDF) rats have reduced interstitial albumin uptake by the lymphatics and treatment with 
rosiglitazone did not increase lymphatic function (45). Interestingly, glitazones are 
agonists for PPARγ and are also used to increase insulin sensitivity in diabetic patients. 
Glitazone therapy, however, increases both fluid retention and peripheral edema risk 
especially in elderly or obese individuals (88, 127, 242). Both aging and obesity are 
linked with impaired lymphatic function that leads to increased peripheral edema, which 
often occurs in the feet and ankles (158, 324) Diabetic patients treated with Glib are less 
likely to develop cardiopulmonary edema than patients given glitazone therapy and do 
not display the same edema risk (50, 233, 314).  
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Adipose dysfunction in MetSyn is definitively linked with the inflammatory state 
and polarization of adipose tissue macrophages (195, 196). Multiple studies have 
suggested a role for CD11b+ macrophages in lymphatic dysfunction (164, 187), however 
their polarization and temporal and spatial association with the lymphatic collecting 
vessels has not been addressed.  Macrophages can produce a multitude of vasoactive 
substances including substance P (7, 55) and NO (187, 191, 323), which each have 
potent effects on lymphatic contractility regulation (352). We have previously described 
a significant reduction in the intrinsic lymph pump capability of the MLV in a rat model 
of high fructose fed MetSyn (357). Recently, others have demonstrated a reduction in 
phasic activity and lymph function in genetic and diet-induced models of obesity, which 
also fit under the umbrella of MetSyn models (25, 262, 330). We have assessed the 
intrinsic pump function of the MLV both in models of LPS-induced peritonitis and high 
fructose fed MetSyn in the rat. We characterized the macrophage recruitment, 
polarization, and association of these macrophage populations with the mesenteric vessel 
dysfunction. Finally we assessed the role of therapeutic levels of the anti-diabetic drug 
Glib, a KATP channel inhibitor, on regulating lymphatic chronotropy and function in the 
MetSyn state. 
 
Materials and Methods  
Animal Handling 
  Sprague Dawley male rats weighing 250g were purchased from Charles River 
and given a week to acclimate. For the LPS model of peritonitis, twenty-four rats were 
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divided into two groups. One group was given intra-peritoneal injections of LPS at 
10mg/kg daily for three consecutive days. The second group was injected with sterile 
phosphate buffered saline (PBS) i.p. as a vehicle control for three consecutive days. 
Seven rats from each group were utilized for isobaric MLV analysis. The remaining five 
rats from each group were utilized for immunohistochemistry (IHC) in the mesenteric 
tissue. Water and feed were available ad libitum except during pre-experiment (16hr) 
fasting.  
Thirty rats weighing 180g were ordered from Charles River for the induction of 
the MetSyn. Twenty rats were given a high fructose feed (HFF) diet (60% fructose, 
ID.89247 Harlan Teklad®, 66% caloric content from fructose) for seven weeks to induce 
the MetSyn, while the remaining ten animals were given standard rodent chow. Water 
and each respective feed were available ad libitum except during pre-experiment (16hr) 
fasting. Ten rats from the MetSyn group and five rats from the control group were 
utilized for isobaric functional analysis of MLV contractility.  The remaining rats were 
used for IHC and RNA collection from the mesentery tissue. All animals were housed in 
a facility accredited by the Association for the Assessment and Accreditation of 
Laboratory Animal Care and maintained in accordance with the policies defined by the 
Public Health Service Policy for the Humane Care and Use of Laboratory Animals, the 
United States Department of Agriculture’s Animal Welfare Regulations and the Scott & 
White Animal Care and Use Committee. 
Serum Analysis  
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Blood was collected in fasted (16hr) rats via the lateral saphenous veins at the 
start and end of the diet period. The saphenous vein was punctured using a 27gauge 
needle and blood was collected in a non-heparinized tube. Blood was allowed to clot for 
1hour at room temperature and spun for ten minutes at 3,000g. Serum was then frozen 
and stored at -80οC. Triglyceride and insulin concentrations were assessed using 
commercially available colorimetric kits, Bioassays® ETGA-200 and an insulin ELISA 
kit Linco® EZMRI-13k, respectively, following the manufacturers' protocols. 
MLV Isolation 
Rats were fasted for sixteen hours and were anesthetized with Innovar-Vet (0.3 
ml kg-1 I.M.), which is a combination of a droperidol-fentanyl solution (droperidol 20 
mg/ml, fentanyl 0.4 mg/ml), and diazepam (2.5 mg/kg IM). A midline excision was 
made and a loop of ileum was carefully exteriorized. Two to three MLV were carefully 
dissociated from the surrounding adipose tissue with care to prevent excess bleeding. 
Vessels were maintained in albumin-supplemented physiological saline solution (APSS, 
in mM: 145.0 NaCl, 4.7 KCl, 2 CaCl2, 1.17 MgSO4, 1.2 NaH2PO4, 5.0 glucose, 2.0 
sodium pyruvate, 0.02 EDTA and 3.0 3-(N-morpholino) propanesulfonic acid (MOPS) 
and 1% w/v bovine serum albumin) at pH 7.4 at 38°C. MLVs were then cannulated onto 
matched pipettes in a CH-1 chamber® (Living Systems) and attached to separate 
pressure reservoirs. Only vessels that did not have apparent constriction sites due to 
damage were used. Vessels were then allowed to equilibrate at pressure 1cmH2O for 
approximately thirty minutes. After the equilibration period each vessel was recorded for 
5 minutes at pressures 1cm, 3cm, and 7cmH2O. Vessels taken from the MetSyn rats and 
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their control counterparts were also stimulated with 1µM, and finally 10µM, Glib at each 
pressure after a fifteen-minute equilibration period. At the end of each experiment the 
bath solution was replaced with calcium-free APSS and maximal diameter at each 
pressure recorded. 
Isolated Vessel Video Analysis  
Lymphatic diameter were traced for each 5 min video capture with a vessel wall-
tracking program developed and provided by Dr. Michael J. Davis (University of 
Missouri-Columbia) (58). Outer lymphatic vessel diameters were tracked 30 times per 
second, providing a tracing of diameter changes throughout the periods of systole and 
diastole. The following analogies to the cardiac pump parameters were derived: 
lymphatic tonic index, contraction amplitude, ejection fraction, contraction frequency, 
fraction pump flow, and systolic/diastolic diameters, as previously described. Statistical 
significance was determined through two-way analysis of variance with Fisher’s post 
hoc analysis using the Statplus® (AnalystSoft) statistical software package. Data are 
represented as means ± standard error (SE) and significance represented independently 
at each figure. 
Immunohistochemistry and RNA/Tissue Collection 
Rats that were utilized for IHC were anesthetized as described above and then 
euthanized via thoracotomy. The mesenteric tissue from the duodenum to the cecum was 
collected. In the LPS-induced peritonitis model, the ileum was excised and pinned in a 
Sylgard-coated dish. Tissues were then fixed in methanol at -20°C for 1hr. Tissue 
collection for the MetSyn rats was performed similarly. Additionally, the cecum of each 
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MetSyn rats was weighed and measured. Remaining mesenteric tissues from MetSyn 
rats, from the ileum and jejunum, were also pinned out and fixed in RNALater ® 
overnight at 4°C for RNA isolation.  
For IHC, fixed tissue was rinsed with PBS and the perivascular tissue was cut 
from the intestinal wall and root of the mesentery, such that two bundles were present in 
each section. These tissues were transferred to a clean dish and blocked with 5% goat 
serum in PBS for 2 hours at room temperature. The tissue was then stained overnight at 
4°C with antibodies recognizing CD163 at 1:200 (AbD Serotec), CD206 at1:100 
(Abcam), and MHCII at 1:200 (Santa Cruz) in combination. Tissues were then washed 
with PBS and stained with AlexaFlour® 488 or 647-conjugated goat secondary 
antibodies at 1:200 for the respective primary antibody host and isotype. Tissues were 
then mounted between two coverslips with Anti-fade® mounting solution to limit the 
restriction in tissue depth. Images were collected at 20x and 40x magnifications using a 
Leica scanning confocal microscope with lymphatic vessels centered in the field of view. 
One to three lymphatic vessels were “tracked” from the intestinal wall towards the root 
of the mesentery per staining combination. Cell counts from five separate 40x images 
and three separate 20x images were averaged per animal to get an accurate 
representation of tissue macrophage polarization and lymphatic vessel association. 
Lymphatic Endothelial Cell Culture 
Mesenteric lymphatic endothelial cells (mLECs) and mesenteric lymphatic 
muscle cells (mLMCs) were both obtained through mesenteric vessel explants. Cells 
were grown in EGM-2MV medium (Lonza) and used at passages 4-7. mLECs were 
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plated at a 60% confluence in a 12-well plate and allowed to grow to a 100% confluence. 
The mLECs were then serum starved with basal EGM media for 2 hours and exposed to 
either EGM-2MV supplemented with vehicle or LPS (20ng/ml) for 24 hours. These 
mLECs were then washed with ice-cold PBS and lysed in Trizol Reagent® (Life 
Sciences). RNA was collected as per the manufacturer’s instructions. The mLMCs were 
plated at approximately 50% confluence and grown in Dulbecco’s modified Eagle’s 
medium (DMEM) with 10% fetal bovine serum (FBS). Upon reaching 80% confluence 
the mLMCs were serum starved for 2 hours in basal DMEM. The media was then 
replaced with DMEM supplemented with 2% serum and either PBS vehicle or LPS 
(20ng/ml) for 24 hours. Finally, the mLMCs were then washed with ice-cold PBS and 
RNA collected as described above.  
RNA Collection and Quantitative Polymerase Chain Reaction (QPCR) Analysis 
RNA was collected from the entire neurovascular bundle in both control and 
MetSyn rats. RNA was stabilized in RNALater at 4οC overnight and then the 
neurovascular bundle was excised and homogenized in Trizol solution. The homogenate 
was then centrifuged for one minute at 1,000g and the lipid content removed to prevent 
interference in the RNA collection, as directed by the manufacturer. RNA from the 
tissues, mLECs, and mLMCs was then converted to cDNA using the Bio-Rad iScript 
cDNA Synthesis Kit® and using 1µg of RNA per reaction. Gene expression was 
analyzed using the ΔΔCt method with beta-actin serving as the housekeeping control. A 
list of genes and the primers used for this method are provided in Table 2. 
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Table 2: QPCR primer list of genes involved in activation of inflammation and  
macrophage polarization 
 
  
Gene Forward Reverse 
β-Actin AAGTCCCTCACCCTCCCAAAAG AAGCAATGCTGTCACCTTCCC 
SM α-Actin CATCAGGAAGGACCTCTATGC CTGATCCACATCTGCTGGAAG 
GAPDH CAATGTGTCCGTCGTGGATCT TGCTTCACCACCTTCTTGATGT 
IL-6 TCCTACCCCAACTTCCAATGCTC TTGGATGGTCTTGGTCCTTAGCC 
CCL2 AGCATCCACGTGCTGTCTC GATCATCTTGCCAGTGAATGAG 
iNOS CAGCCCTCAGAGTACAACGAT CAGCAGGCACACGCAATGAT 
MCSF CCATCGAGACCCTCAGACAT TGTGTGCCCAGCATAGAATC 
GMCSF GACCATGATAGCCAGCCACT TTCCAGCAGTCAAAAGGGATA 
CCL1  CTTAGCTTGGTCCTGGTTCTC  GAATCTTCTTCTGGCTGTACCT 
TGFβ CGTGGAAATCAATGGGATCAG GGAAGGGTCGGTTCATGTCA 
Lyve-1 AGGCTGAAGTTTAGGTGCACGAGA GAGCCAACAGTGGCTTGCTTCTTT 
Prox-1 TGTCCGACATCTCTCCTTATTCG ACGGGTGTAAAAGAACATGAGCT 
SM22 AGGCAGCTGAGGATTATGGA CTGCCCAAAGCCATTACAGT 
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Results 
LPS-Induced Peritonitis Severely Impairs MLV Pump Function 
Mesenteric vessels isolated from LPS-injected rats had a significantly reduced 
diastolic diameter only at a pressure of 7cmH2O (Figure 3). However, this was also 
associated with reduced vessel tone at pressures of 3cm and 7cmH2O (Figure 3). Four of 
the seven lymphatic vessels isolated from LPS-injected rats exhibited no phasic 
contractions at any intramural pressure. The remaining three lymphatic vessels isolated 
from these animals displayed spontaneous lymphatic contractions but had abnormally 
low contraction frequency. This resulted in a dramatic and significant reduction in 
lymphatic frequency and lymph pump flow (Figure 4). In contrast, the control vessels 
had robust contractility and pressure sensitivity. The four non-contracting vessels were 
excluded from the analysis of the stroke volume, which was not significantly different 
from control MLV stroke volume. A summary of the contractile parameters for the LPS-
injected rats is listed in Table 3. 
Macrophage Polarization and Association with the MLVs 
 Mesenteric whole mounts were prepared from control and LPS-injected rats to 
examine the association of macrophages with the MLV and their polarization index. 
Mesenteric arcades were fixed and stained for the M2 markers CD206 (macrophage 
mannose receptor) and the scavenger receptor CD163. The mesenteric whole mounts 
were also stained for MHCII to identify M1 polarized macrophages. We took panoramic  
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Figure 3. Outer diastolic diameter (ODD) and tonic index in MLVs isolated from control 
and LPS groups. MLVs isolated from LPS-injected rats had a significantly reduced 
diameter at a pressure of 7cmH2O.  Paradoxically, there was also a significant reduction 
in vessel tone at pressures of 3cm and 7cmH2O. Data are presented as Mean ±	 standard 
error of the mean	 (SEM). N= 7 for each cohort. 2-way ANOVA * denotes significance 
at p < 0.05 
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Figure 4. Contraction frequency and ejection fraction in LPS MLVs. MLVs isolated 
from LPS rats had a critical loss in spontaneous contractions that severely inhibited the 
lymph pump. Data are presented as Mean ±	 SEM. N= 7 for each cohort. 2-way ANOVA 
* denotes significance at p < 0.05 
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Table 3. Contractile parameters of MLV contractility of control and LPS groups 
Mean ± SEM Pressure (cmH2O) P=1 P=3 P=7 
Outer Diastolic 
Diameter (uM) 
Control MLVs 95.2 ± 8.5 127 ± 9.1 150 ± 8 
LPS MLVs 102 ± 6.8 112 ± 9.4 123.9 ± 10.5 
          
Contraction 
Frequency per 
Minute 
Control MLVs 9.13 ± 1.53 12 ± 1.72 
15.1 ± 
1.78 
LPS MLVs 0.69 ± 0.33 
1.86 ± 
0.94 
2.86 ± 
1.51 
          
Stroke Volume 
(nL) 
Control MLVs 3.34 ± 0.79 
6.50 ± 
1.15 
7.11 ± 
1.11 
LPS MLVs 3.07 ± 2.10 
4.46 ± 
2.76 
3.77 ± 
2.04 
          
Lymph Pump 
Flow (nL/Min) 
Control MLVs 24.3 ± 4.23 
75.9 ± 
18.4 105 ± 18.1 
LPS MLVs 1.76 ± 1.21 
10.2 ± 
8.33 
13.1 ± 
10.5 
          
Tonic Index (% 
constriction) 
Control MLVs 7.42 ± 2.44 
9.18 ± 
1.39 
7.86 ± 
1.99 
LPS MLVs 6.10 ± 1.54 
4.83 ± 
0.87 
3.39 ± 
0.76 
 
Data are presented as Mean ± SEM for outer diastolic diameter, lymphatic contraction 
frequency, stroke volume, lymph pump flow, and tonic index. 
 
 
 
 
 
 
  
48 
images at 20x magnification in control rats to understand the macrophage tissue 
investiture on a large scale. We found that the perivascular adipose tissue was heavily 
invested with resident tissue macrophages that stained for both CD163 and CD206 
(Figure 5). These cells were dispersed throughout the adipose tissue and spatially 
arranged in the clear mesenteric membrane that coats the tissue. We found that 
CD163+CD206+ macrophages also are found in direct contact with the lymphatic vessel 
itself (Figure 5). These cells commonly displayed the classical adipose tissue 
macrophage geometry as they were wedged between the hexagonal shaped perivascular 
adipocytes. However, this geometry was lost in the clear field mesenteric sheath or when 
they were associated with lymphatic vessels (Figure 5). CD163-CD206+ macrophages 
were present in low numbers with the vast majority of macrophages staining positive for 
both M2 markers. Macrophage cell density appeared highest near the MLV and counting 
at 40x magnification demonstrated a slight tropism toward the mesenteric collecting 
vessel. MHCII+ cells displayed a strong tropism to the lymphatic vessel or other vascular 
structures (Figure 6). Double staining with CD206 revealed a dichotomy in staining 
profiles observed, with CD206+MHCII- and MHCII+CD206- cells (Figure 6). MHCII+ 
cells displayed an elongate morphology with multiple cellular projections and dendrites 
when found along the vessel. MHCII+ cells in the peripheral tissue were generally 
smaller in size and had a circular phenotype. There was evidence for a small population 
of double positive MHCII+CD206+ cells whose morphology most closely matched the 
smaller MHCII+ circular cells.  
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Figure 5. Panoramic view of immunofluorescence for M2 macrophages in a rat 
mesenteric whole mount prep. Macrophages were fixed in methanol and stained with 
CD206 (red) and CD163 (green). The majority of stained cells are CD163+CD206+ and 
are found within the clear-field tissue (A), the adjacent adipose (B), and the along the 
lymphatic vessel(C). There is also a small population of CD163-CD206+ cells that have a 
different morphology in that they are significantly smaller and ovoid (arrows). 20x 
magnification B-C, 40x magnification A.  
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Figure 6. Immunofluorescence of M1 and M2 macrophage investiture in normal rat 
whole mount mesenteric tissue. Immunofluorescence identifies MHCII (Blue) and 
CD206 (Red) positive cells. (A) 20x magnification of control whole mount of normal rat 
mesentery demonstrates the investiture of MHCII+ cells that display a tropism towards 
the lymphatic rather than within the tissue. (B) 40x magnification of mesenteric tissue 
stained for both MHCII (Blue) and CD206 (red). There is a dichotomy in staining 
profiles observed, with both CD206+MHCII- and CD206-MHCII+ cells, but both cells 
can be found associated with the MLV. Straight white lines denote the lymphatic vessel 
borders.  
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LPS-Induced Peritonitis Increases Macrophage Accumulation and a M2 Phenotype 
LPS injection caused a significant accumulation of macrophages in the 
mesenteric neurovascular bundle and peripheral tissue (Figure 7) and fibrotic appearance 
of the mesenteric sheath. These cells displayed a noticeable change in their morphology 
both within the perivascular tissue and the mesenteric sheath (Figure 7). Macrophages in 
the mesenteric sheath displayed a unique stellate morphology and were larger compared 
to their control counterparts. CD163 positive macrophages displayed an activated 
phenotype with multiple cellular extensions and spine-like dendrites within the tissue 
space. In contrast, the majority of mesenteric vessel-associated macrophages were ovoid 
in morphology suggesting they could be in the process of migrating. Macrophages were 
still predominantly double positive for both CD163 and CD206 (Figure 8) in the LPS-
injected rats; however there was a significant increase in the presence of the CD163-
CD206+ polarization. The CD163-CD206+ phenotype displayed a strong tropism for the 
lymphatic collecting vessel (Figure 8). The CD163-CD206+ morphology was maintained 
as small ovoid cells with a prominent nuclear hole. The accumulation of macrophages in 
the tissue made the identification of lymphatic collecting vessels through 
autofluorescence difficult due to the large number of macrophages that were associated 
with the vessel. Each image stack was divided into 3 segments to allow proper three-
dimensional counting. LPS injection increased the macrophage accumulation in the 
mesentery more than two-fold (Figure 9). The CD163-CD206+ phenotype displayed the 
largest fold change with a four-fold increase. Interestingly, there was no significant 
accumulation of MHCII+ cells in the LPS-injected rats (Figure10). 
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Figure 7. Macrophage accumulation and activation in the LPS rat mesentery. Mesenteric 
whole mounts taken from control (A and B) and LPS-injected (C and D) rats were 
stained with CD163 and scanned at 20x (A and C) and 40x (B and D). White lines 
denote the walls of a lymphatic collecting vessel.  
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Figure 8. Evidence of M2 macrophage phenotypes in the LPS-injected rat mesentery. 
Mesenteric arcades from control (A and B) and LPS-injected (C and D) rats were stained 
for CD163 (green) and CD206 (red). Images of 40x magnification are shown. Arrows 
indicate the single positive CD163-CD206+ cells. MLV are outlined with white lines.  
 
v 
v 
C D 
75µm 75µm 
  
54 
 
Figure 9. Quantification of the M2 macrophage phenotypes in control and LPS-injected 
rats. A minimum of five 40x image stacks were quantified and averaged per animal with 
1µm slices and approximately 30-50 slices per stack focused around MLV. Cells that 
were in contact with the vessel were counted in association with the vessel and the 
remaining cells considered to be in the frame. Data are presented as Mean ±	 SEM. N= 4 
for each cohort. 1-way ANOVA * denotes significance at p < 0.05 
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Figure 10. Lack of M1 polarized macrophages in the LPS-injected rat mesentery. 
Control (A) and LPS-treated rats (B) were stained for MHCII (blue) and CD206 (red). 
MLVs are outlined with white lines. (C) Summary data showing the number of MHCII+ 
cells. Data are presented as Mean ±	 SEM. N= 4 for each cohort. 1-way ANOVA * 
denotes significance at p < 0.05 
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Gross Histological Alterations in the Cecum and Perivascular Adipose in MetSyn Rats 
We observed that the cecum was abnormally small in the MetSyn rats and fasted 
cecum wet weight was roughly half that of controls when normalized to body weight 
(Figure 11 A-C). Mesenteric whole mount tissues that were fixed overnight at 4°C in 
RNALater provide further evidence for enlargement of the perivascular adipose tissue 
that encases the mesenteric neurovascular bundle (Figure 11D and 11E). 
High-Fructose-Induced MetSyn Rats Exhibited Macrophages Skewed Toward M1 State 
Immunofluorescence was also preformed on mesenteric arcades collected from 
MetSyn rats. Tissues were fixed and stained in the same manner as described for the 
LPS-injected rats. The dichotomy in staining for CD163/CD206 and MHCII staining 
was observed in control bundles; however the MetSyn tissues displayed a significant rise 
in the amount of CD163+MHCII+ cells (Figure 12). MetSyn mesenteric bundles had a 
modest but significant increase in the number macrophages (Figure 13) that was directly 
affected by the rise in CD163+MHCII+ double positive cells (Figure 13). There were no 
changes in the population of CD163+CD206+ cells nor was there an increase in the 
number of CD163-MHCII+ cells (Figure 13). 
MLV Function is Not Restored with Therapeutic Levels of Glib in MetSyn Rats 
MLVs were isolated from control and MetSyn rats and exposed to intramural 
pressures of 1, 3, and 7cmH2O in APSS solution. Approximately half of the MetSyn 
MLVs demonstrated significantly reduced lymph pump flow as a function of a  
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Figure 11. High fructose feeding-induced MetSyn results in gross histological changes in 
the cecum and mesenteric tissue. Cecum size in control (A) and MetSyn (B) rats is 
shown; (C) Cecum weight to body weight is shown for control and MetSyn rats. 
Mesenteric tissue bundles fixed in RNALater® overnight at 4oC illuminates the 
increased adiposity in the perivascular depots of the mesenteric neurovascular bundles 
(D, Control; E, MetSyn). Data are presented as Mean ±	 SEM. N= 6 for each cohort. 1-
way ANOVA * denotes significance at p < 0.05 
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Figure 12. Macrophage profile in the neurovascular bundles of the mesentery in control 
and MetSyn rats. Representative image of a 40X field of view stained for CD163 (A,D 
green) and MHCII (B,E blue) to demonstrate single or dual staining (C, F merge). A, B, 
and C Control mesentery; D, E, and F MetSyn mesentery. White asterisks in C and F 
demonstrate CD163+MHCII+ cells. The lymphatic vessel is outlined with white lines. 
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Figure 13.  Summary data showing the number of single or double positive CD163, 
MHCII cells. The number of total positive cells (A), CD163+MHCII+ cells (B), CD163-
MHC+ cells (C) and CD163+MHCII- cells (D) are shown. Data are presented as Mean ±	 
SEM. N= 6 for each cohort. 2-way ANOVA * denotes significance at p < 0.05 
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significantly lower phasic contraction frequency (Figure 14) and stroke volume (MSlo) 
(Figure 15).  Additionally, the remaining vessels displayed abnormally high contraction 
frequencies (MShi) that were greater than control vessel frequency (Figure 14), but with 
a significantly reduced ejection fraction (Figure 15). Lymph pump flow in the MShi 
vessel population was not significantly different than in controls despite the altered 
contractility. Vessel diameters and tonic indexes were not significantly different in 
control, MSlo, or MShi groups (Figure 16). Control and MSlo vessels were also exposed 
to 1µM Glib (Glib) and 10µM Glib at each pressure to determine if Glib could restore 
lymph pump function through the inhibition of KATP channels. Glib at 1µM in MSlo 
vessels did not increase lymph pump flow despite an increase in phasic contraction 
frequency (Figure 17). Additionally, 1µM Glib did not significantly alter contraction 
frequency or lymph pump flow at pressures or 3 or 7cmH2O (Figure 17). Ejection 
fraction, stroke volume, and vessel tone were all unchanged from basal values by the 
addition of 1µM Glib (Figure 18). To determine if the contraction frequency reduction 
was regulated by poor pacemaker function we maximally activated control and MSlo 
MLVs with 10µM Glib. Glib at 10µM dramatically increased contraction frequency in 
both control and MSlo MLVs. However, 10µM Glib significantly increased lymph pump 
flow (Figure 17) at only pressure 3cmH2O in MSlo MLVs and did not significantly 
affect control lymph pump flow. Ejection fraction and stroke volume fell in control 
vessels, but not in MetSyn rats, at pressures of 3 and 7cmH2O (Figure 18) in response to 
10µM Glib.  A summary of the contractile parameters is listed in Table 4. 
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Figure 14. Impaired contractile frequency and lymph pump flow in the MetSyn MLV. 
MLVs isolated from MetSyn rats displayed two phenotypes and were separated into 
MSlo (<10 contractions per minute) and MShi (>10 contractions per minute) populations 
based on their contraction frequency at pressure 1cmH2O. Data are presented as Mean ±	 
SEM. n=10 control, 9MSlo, 11MShi. 2-way ANOVA and Fisher post-hoc. * denotes 
p<0.05; ^ denotes p<0.1 comparing MSlo or MShi versus control, # denotes p<0.05; “ 
denotes p<0.1 comparing MSlo versus MShi. 
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Figure 15. MLV from MetSyn rats have reduced stroke volume and ejection fraction. 
MLVs isolated from MetSyn rats displayed two phenotypes and were separated into 
MSlo (<10 contractions per minute) and MShi (>10 contractions per minute) populations 
based on their contraction frequency at pressure 1cmH2O. Data are presented as Mean ±	 
SEM. n= 10 control, 9MSlo, 11MShi. 2-way ANOVA and Fisher post-hoc. * denotes 
p<0.05; ^ denotes p<0.1 comparing MSlo or MShi versus control. 
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Figure 16. Vessel outer diastolic diameter and vessel tone are normal in the MLVs from 
MetSyn rats. MLVs isolated from MetSyn rats displayed two phenotypes and were 
separated into MSlo (<10 contractions per minute) and MShi (>10 contractions per 
minute) populations based on their contraction frequency at pressure 1cmH2O. Outer 
diastolic diameter (ODD) and tonic index was determined. Data are presented as Mean ±	 
SEM. n= 10 control, 9MSlo, 11MShi. 2-way ANOVA and Fisher post-hoc.  
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Figure 17. The effect of Glib on MLV contraction frequency and lymph pump flow in 
MetSyn MLVs. MLVs isolated from MetSyn rats that demonstrated a contraction 
frequency below 10 contractions per minute were characterized as MSlo. Data are 
presented as Mean ±	 SEM. n= 10 control and 9 MSlo. 2-way ANOVA and Fisher post-
hoc. * denotes p<0.05; ^ denotes p<0.1 comparing MSlo versus control, # denotes 
p<0.05; “ denotes p<0.1 comparing Glib versus APSS within each cohort.
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Figure 18. The effect of Glib on MLV stroke volume and ejection fraction in MetSyn. 
MLVs isolated from MetSyn rats that demonstrated a contraction frequency below 10 
contractions per minute were characterized as MSlo. Data are presented as Mean ±	 
SEM. n= 10 control and 9 MSlo for APSS pressure responses and n=4 for each cohort 
for Glib responses. 2-way ANOVA and Fisher post-hoc. * denotes p<0.05; ^ denotes 
p<0.1 comparing MSlo versus control, # denotes p<0.05; “ denotes p<0.1 comparing 
Glib versus APSS within each cohort.  
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Table 4. Contractility parameters from the control and MetSyn MLVs 
 
Data are presented as Mean ± SEM for outer diastolic diameter, lymphatic contraction 
frequency, stroke volume, lymph pump flow, and tonic index. n=10 control, 9MSlo, 
11MShi for pressures of 1, 3, and 7cmH2O. n= 4 for control and MSlo vessels stimulated 
with Glib. 
  
Mean ± 
SEM 
Pressure 
(cm H2O) P=1 P=3 P=7 P=1 1Glib P=3 1Glib P=7 1Glib P=1 10 Glib P=3 10 Glib P=7 10Glib 
Outer 
Diastolic 
Diam. (uM) 
Control 128 ± 6.50 144 ± 7.4 154 ± 7.9 139 ± 16.8 154 ± 19.0 163 ± 20.0 133 ± 12.9 150.6 ± 12.5 158 ± 12.2 
Mslo 117 ± 7.2 130 ±7.2 142 ±7.9 111 ± 13.7 123 ± 12.5 130 ± 12.2 119 ± 0.8 139 ± 2.4 148 ± 3.0 
Mshi 127.5 ±9.8 141± 9.5 150 ± 8.5 nd nd nd nd nd nd 
Contraction 
Frequency 
per Minute 
Control 8.7 ± 1.0 11.9 ± 1.1 11.9 ± 1.5 12.3 ± 1 14.0 ± 3.1 13.5 ± 3.7 21.1 ± 3.0 22.6 ± 2.1 21.6 ± 2.8 
Mslo 5.8 ± 0.7 7.2 ± 0.7 8.7 ± 1.6 12.1 ± 0.8 10.4 ± 1.4 8.7 ± 1.3 18.4 ± 2.7 16.7 ± 1.7 14.7 ±1.2 
Mshi 14.6 ± 1.3 17.1 ± 1.4 16.1 ± 1.4 nd nd nd nd nd nd 
Stroke 
Volume (nL) 
Control 6.31 ± 0.8 7.8 ± 0.99 7.08 ± 1.47 7.3 ± 2.8 8.6 ± 4.3 6.3 ± 3.2 4.9 ± 0.8 4.2 ± 1.0 2.6 ± 1.5 
Mslo 4.02 ± 0.81 4.77 ± 0.90 4.10 ± 0.61 3.7 ± 1.7  4.7 ± 1.6 3.7 ± 1.3 3.2 ± 0.8 4.4 ± 0.9 2.6 ± 0.6 
Mshi 5.17 ± 1.28 5.55 ± 1.38 3.78 ± 0.96 nd nd nd nd nd nd 
Lymph 
Pump Flow 
(nL/Min) 
Control 52.7 ± 7.8 91.4 ± 13.7 77.2 ± 12.8 82.0 ± 19.8 97.5 ± 13.7 65.1 ± 24.4  83.2 ± 21.8 92.4 ± 14.0 49.8 ± 11.6 
Mslo 22.4 ± 4.5 32.5 ± 5.3 32.1 ± 5.0 40.3 ± 16.8 42.8 ± 11.8 30.4 ± 8.6 50.1 ± 11.4 67.0 ± 8.1 41.6 ± 4.8 
Mshi 70.0 ±16.1 82.8 ± 15.8 54.8 ±12.1 nd nd nd nd nd nd 
Tonic Index 
(% 
constriction) 
Control 14.2 ± 2.1 10.3 ± 1.7 8.3 ± 1.8 8.7 ± 2.9 7.4 ± 1.9 5.2 ± 1.7 10.9 ± 2.9 7.6 ± 0.9 6.0 ± 1.8 
Mslo 14.6 ± 1.6 11.5 ± 1.33 7.6 ± 1.3 11.5 ± 3.3 7.3 ± 1.1 5.6 ± 1.0 16.5 ± 2.7 8.9 ± 0.6 5.5 ± 0.2 
Mshi 13.0 ± 2.1 9.1 ± 1.5 7.3 ± 1.2 nd nd nd nd nd nd 
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Macrophage Recruitment and Polarization Factors and iNOS Expression 
 RNA was also collected from the mesenteric bundles of MetSyn and control rats. 
Levels of MCP-1 and iNOS mRNA were both significantly elevated in the mesenteric 
tissue of MetSyn animals (Figure 19). We cultured mLECs and mLMCs and stimulated 
them with 20ng/ml of LPS for a 24-hour period. Inflammatory gene expression and 
macrophage maturation markers were assessed using QPCR and the ΔΔCt method, with 
β-actin (βAct) and smooth muscle α-actin (SMA) used as housekeeping controls. LPS-
treated mLECs expressed significantly elevated levels of glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH), MCSF, IL-6, Prox-1, and TNFα when compared to vehicle-
stimulated mLECs (Figure 20). The mLECs dramatically increased the expression of 
GMCSF, iNOS, monocyte chemoattractant protein 1 (CCL2), and chemokine ligand 1 
(CCL1), as abundance of these RNAs increased greater than 10 fold in response to LPS 
(Figure 20). The mLMCs also up-regulated genes associated with tissue inflammation, 
including GAPDH, MCSF, GMCSF, TGFβ, and transgelin (SM22) (Figure 21). CCL2, 
IL-6, and iNOS expression were highly activated in mLMC cultures in response to LPS 
stimulation (Figure 21). The threshold values of each gene tested are listed in Table 5. 
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 Figure 19. Mesenteric neurovascular bundles have elevated expression of CCL2 and 
iNOS. Mesenteric neurovascular bundles were fixed overnight in RNALater® at 4oC and 
RNA extracted. Relative gene expression was calculated as described in the Methods 
section. MetSyn neurovascular bundles had higher expression of both iNOS (2.5 fold) 
and CCL2 (6 fold) as compared to control tissues. Data are presented as Mean ±	 SEM. 
N=6; * denotes significance at p<0.05 
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Figure 20. LECs increase expression of inflammatory genes and macrophage maturation 
genes in response to LPS. LECs were treated either with PBS (vehicle, control) or 
20ng/ml LPS for 24 hours. RNA was collected and subjected to real time PCR using 
specific primer sets. Normalized expression was determined as described in the Methods 
section. (A) LECs increased expression of GAPDH, MCSF, IL-6, Prox-1, and TNFα in 
response to LPS stimulation. (B) LECs demonstrated a dramatic increase in the 
expression of iNOS, CCL1, CCL2, and GMCSF (1673 fold higher) in the LPS-treated 
group as compared to control group. Data are presented as Mean ±	 SEM. N=3; * 
denotes significance at p<0.05 
  
70 
 
 
 
Figure 21. mLMC increase expression of inflammatory genes and macrophage 
maturation genes in response to LPS. The mLMCs were treated either with PBS 
(vehicle, control) or 20ng/ml LPS for 24 hours. RNA was collected and subjected to real 
time PCR using specific primer sets. (A) mLMC-treated with LPS showed a significant 
increase in the  expression of GAPDH, MCSF, GMCSF, TGF-beta, and SM22 as 
compared to the control cells. (B) IL-6, CCL2, and iNOS expression was highly 
increased in response to LPS stimulation. Data are presented as Mean ±	 SEM. N=3; * 
denotes significance at p<0.05
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Table 5. Gene threshold cycle values for both mLECs and mLMCs after stimulation with 
LPS. 
 
The threshold cycle values from the QPCR of treated mLECs and mLMCs. Cells were 
exposed to vehicle control (PBS) or 20ng/ml of LPS for 24hrs. RNA (1µg) was 
converted to cDNA and QPCR was used to determine the relative expression of genes 
that regulate tissue inflammation and macrophage recruitment and polarization.  
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Discussion 
The presented data have demonstrated that both acute (LPS-injection) and 
chronic (MetSyn) inflammatory conditions impair the intrinsic pump characteristics of 
the lymphatic vessel. In addition, an increase in macrophage accumulation and altered 
macrophage polarization in the surrounding tissue and in contact with mesenteric 
collecting lymphatic vessels are seen in both of these models. Furthermore this study has 
provided evidence for a direct role for the lymphatic tissue in shaping macrophage 
homeostasis and polarization through the expression of macrophage chemoattractant and 
maturation factors. These functional characteristics of lymphatics may contribute to 
resident tissue macrophage homeostasis under physiological and pathophysiological 
conditions (Figure 22) such as MetSyn or infection and may contribute to the increased 
risk for lymphedema in MetSyn. 
Our data provides the first characterization of the macrophage polarization and 
spatial association with MLVs in both the LPS-induced peritonitis and MetSyn. The 
recruitment and association of macrophages with lymphatic tissues have been previously 
documented with LPS-induced inflammation in a mouse model, although macrophage 
polarization has not been addressed in these studies (164, 187, 191). A mouse model of 
LPS-induced peritonitis demonstrated a role for CD11b+ myeloid cells in lymphatic 
dysfunction and poor fluid clearance in the diaphragm (164). These macrophages are a 
source of the pro-lymphangiogenic factors vascular endothelial growth factor C and D 
(VEGFC, VEGFD) that regulate endothelial sprouting and proliferation. These  
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Figure 22. Schematic of the crosstalk between lymphatic collecting vessels and 
macrophage populations in the different disease models. MetSyn increases 
CD163+MCHII+ M1 skewing of the macrophage population. LPS-induced peritonitis 
also increases the accumulation of CD163-CD206+ and CD163+CD206+ cells. 
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investigators demonstrated a role for CD11b+ cells as initiators of fibrosis and 
lymphangiogenesis (164). Additionally, functional parameters of lymphatic contractility  
were not measured in the collecting vessels that drain the tissue. Macrophage influx into 
the lymphatic space utilizes both expansion of monocyte-derived cells and expansion of 
resident tissue macrophages. LPS-activated CD11b+ macrophages can also activate a 
lymphatic endothelial cell progenitor phenotype and contribute to the inflammation-
driven lymphangiogenesis (120). We did not address the role of lymphangiogenesis in 
the LPS-induced inflammation or MetSyn models and focused our efforts on describing 
the contractility changes that are required for proper lymphatic function. However, LECs 
can express the macrophage mannose receptor (CD206) (142, 202). It is a distinct 
possibility that the morphology of the CD163-CD206+ cells is indicative of LECs or 
macrophage-derived lymphatic endothelial cell precursors. However, the CD163-
CD206+ cells were brightly positive for CD206 and observed in the tissue without 
association with the lymphatic vessel. The M2b polarization is induced in response to 
TLR agonist and immune complexes. M2b macrophages are characterized as a quasi-
inflammatory phenotype that produces both IL-10 and TNFα, while expressing a high 
level of iNOS and CCL1 (218, 220). CD206 expression is associated with the TGFβ and 
IL-4 and STAT6 signaling axis that has been described in other models of peritoneal 
inflammation. TGFβ can stimulate the M2b phenotype(311) and is critical to the 
resolution of peritonitis (327). M2b macrophages have been previously described in the 
peritoneum of murine burn models, demonstrating a critical role for CCL1 in the 
regulation and proliferation of the M2b phenotype (11, 165). Our results (Figures 20 and 
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21) show that both mLMCs and LECs express high levels of CCL1 and GMCSF in 
response to LPS stimulation, suggesting a potential mechanism whereby lymphatic 
vessels contribute to the stromal environment for macrophage proliferation and 
activation. This has relevant implications in tissue inflammation as macrophages reside 
along, and in the vicinity of, lymphatic vessels under physiological and 
pathophysiological conditions. Macrophage proliferation and polarization have been 
recently linked to exposure level of either MCSF or GMCSF to induce a M2 or M1 
response, respectively (75, 174). The majority of macrophages in the control mesenteric 
tissue resembled an M2a phenotype, characterized by double staining for 
CD163+CD206+, consistent with reports for adipose tissue macrophages. The 
CD163+CD206+ phenotype expanded significantly in the LPS-injected model and was 
closely associated with lymphatic tissues. This is likely a chemoattractant response to 
CCL2 and our data supports previous reports of CCL2 up-regulation upon TLR 
activation (245).  
LPS has been historically used to activate an M1 phenotype in macrophage in the 
in vitro systems. The M1 phenotype is also induced by GMCSF exposure and is 
characterized by increased expression of MHCII, increased co-stimulatory molecule 
expression, and inflammatory cytokine production (91, 174). We did not observe a 
significant increase in the expression or presence of MHCII positive cells in response to 
LPS despite the dramatic expansion of macrophages. Previous reports have suggested a 
role of glucocorticoid production in the maintenance of the M2 polarization and 
expression of CD163 in the peritoneal macrophages (265). Additionally, daily LPS 
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administrations can result in endotoxin tolerance that results in down regulation of TLR4 
and increases anti-inflammatory gene expression such as IL-10 and TGFβ (234, 358) 
and may suggest a role of peritoneal M2b macrophages. In the mouse, iNOS expression 
strongly correlates with the either the M1 or M2b polarization (195, 200, 219). Extensive 
studies with rat macrophages have yet to be been done to confirm this paradigm, and the 
iNOS expression in human macrophages is not clear (241, 268, 269). Furthermore rat 
peritoneal macrophages have high levels of NO production that is also strain-dependent 
and may not be limited to specific polarizations(186, 221). Investigations into the 
expression of iNOS in the rat macrophage populations will be critical to determining 
further roles for macrophage polarization function and coordination of lymphatic 
function. 
MLVs from LPS-injected rats had severely impaired lymphatic contractility. 
Phasic contraction frequency was absent in half the vessels studied and reduced function 
was described in the remaining three vessels that maintained phasic contractions. The 
inhibition in contraction frequency and decreased tonic index fit very well with the 
current understanding of overproduction of NO, a potent inhibitor of lymphatic 
contractility (323). It is likely that the CD163+CD206+ and/or the CD163-CD206+ cells 
express iNOS despite displaying evidence for a M2 phenotype and were responsible for 
the lymphatic dysfunction in our isobaric preps (186, 221). Others have demonstrated a 
role for iNOS-expressing CD11b+ Gr1+ monocytes in the suppression of mouse popliteal 
lymphatic contractility in response to oxazolone-driven inflammation (187). However, 
this study was performed using intra-vital microscopy of a lymphatic vessel in vivo and 
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would be subject to vasoactive substances or cells carried in the lymph and potentially 
different tissue pressures. In our studies, we isolated lymphatic vessels from the tissue 
and flushed any cells or lymph prior to experimentation allowing us to set specific and 
consistent pressure stimuli. This, in turn, allowed for a critical assessment of the intrinsic 
contractility and lymph pump function by a single lymphangion and its embedded 
resident macrophage population. Previous work in our lab has demonstrated that 
macrophages are embedded in the vessel and are present on isolated lymphatic vessel 
preps (unpublished data). Regional activation of inflammation and altered macrophage 
polarization may play a significant role in the determination of lymphedema risk in 
unilateral cases. 
We have also provided evidence for the lymphatic dysfunction in the MetSyn 
state. Lymph pump flow inhibition has been described in other models of chronic 
inflammation. TNBS-induced ileitis caused significant inhibition of MLV pump in 
guinea pigs that was partially restored by a NOS inhibitor and the KATP channel blocker 
Glib (204, 340). A rat model of TNBS-induced colitis also demonstrated impairment of 
MLV contractility and poor lymph flow due to regional inflammation in the small 
intestine (unpublished results). We have previously reported that MLV have poor 
lymphatic function in a high fructose fed rat model of MetSyn (357). Other investigators 
have replicated these results in genetic and diet-induced models of obesity and the 
MetSyn state in the mouse(25, 262, 330). Lymphatic dysfunction in MetSyn is 
consistently due to a reduction in phasic contraction frequency that significantly lowers 
lymph pump flow. A similar dysfunction in MetSyn MLVs is reported in this study with 
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the addition of a new MLV contractile response that has not been previously described. 
We observed that approximately half of the MLVs isolated from MetSyn rats displayed 
an abnormally high basal contraction frequency (MShi >10beats/minute at 1cmH2O) that 
was significantly higher than control vessels. However, indices of contraction strength 
both were significantly reduced, resulting in no net change in the lymph pumping ability. 
Thus we report that the MetSyn has two patterns of lymphatic dysfunction: 1) a low 
contraction frequency and potentially low ejection fraction, and 2) a high contraction 
frequency and sharply reduced contraction strength. Despite a similar reduction in 
contraction frequency, MetSyn vessels displayed a different phenotype from LPS-
injected contractility responses that were also marked by low tone, suggesting an 
overproduction of NO. In contrast, oxazolone-induced inflammation in the mouse 
induced a similar dichotomy in popliteal lymphatic contractility, demonstrating both 
high frequency and low frequency behavior (187). Both NO and ROS have significant 
effects on lymphatic vessel contractility (204, 355, 356). Regional inflammation and the 
regulation of both NO and reactive oxygen species may explain the origin of these 
different contractile patterns. We also assessed the ability of the anti-diabetic drug Glib 
to increase the lymph pump flow in MSlo rats due to its lower risk of edema compared 
to other anti-diabetic drugs. Glib acts on KATP channels to increase membrane potential 
and increase membrane depolarization frequency. Serum levels for patients on Glib 
spike to as high as 1µM in the serum and we utilized that as our therapeutic 
concentration. We found that 1µM Glib had little effect on MLV contractility in either 
control or MSlo vessels and thus may not have any therapeutic benefit in regards to 
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lymphatic function. Glib (10µM) was able to restore lymphatic contractility in a guinea 
pig model of ileitis (204, 321). We found that 10µM Glib significantly increased 
contraction frequency at each pressure in both control and MSlo rats. Despite the 
increase in frequency, lymph pump flow was not significantly increased due to a 
reduction in stroke volume in control vessels. High dose Glib increased lymph pump 
flow in the MSlo MLVs only at a pressure of 3cmH2O. This, in part, may be explained 
by the loss of pressure sensitivity by pacemaker cells in MetSyn rats in response to Glib. 
Control vessels increased their contraction frequency in response to pressure and this 
pressure sensitive regulation was also observed in response to glibenclamide stimulation 
(100, 318). In contrast to MSlo vessels that lost pressure sensitivity under both 1µM and 
10µM Glib, indicating lymphatic pacemaker impairment in MSlo vessels and contributes 
to the lymphatic dysfunction in MetSyn. 
The macrophage accumulation and polarization is also altered in the mesenteric 
tissue of MetSyn rats. In contrast to the LPS model, we found only a modest increase in 
macrophage accumulation that was specifically due to the increased accumulation of 
CD163+MHCII+ cells. We believe this fits well with previous reports of adipose tissue 
macrophage polarization toward an M1 state (195). We also found elevated expression 
of CCL2 and iNOS in the mesentery of MetSyn rats. Dietary endotoxin is a significant 
contributor to the inflammation in the adipose tissue and liver, and is a key driver in the 
pathogenesis of MetSyn (35, 36). Dietary endotoxin is directly linked to chylomicron 
production and the MLVs are the transport route for chylomicrons produced in the 
intestine (105). It is possible that mesenteric vessels can sense luminal dietary 
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endotoxins, such as LPS, and regulate macrophage polarization and homeostasis through 
the production of various cytokines, as previously stated. Previous studies have 
demonstrated that the lymphatic endothelium expresses TLRs and is sensitive to most 
TLR agonists (155, 245). Infection of LECs with cytomegalovirus also increases the 
production of GMCSF (90). Our data showing an increase in the production of MCSF 
and GMCSF in LECs in response to LPS suggest a novel role for the lymphatic 
endothelium in the regulation of the resident macrophage homeostasis. 
 In conclusion, the results presented in this study have provided new evidence 
linking alterations in macrophage activation and polarization with direct and controlled 
measures of lymphatic vessel contractility under acute and chronic inflammatory 
conditions. Data have also demonstrated a stromal function for mLECs and mLMCs in 
the regulation of macrophage homeostasis through the production of MCSF, GMCSF, 
and CCL1. Lymphatic dysfunction was apparent despite a lack of gross obesity in 
MetSyn group. An increase in perivascular adipose expansion has been observed in 
MetSyn animals that are associated with macrophage polarization skewed to a M1 
phenotype. Whereas in the LPS-treated group there was no obvious change in the 
perivascular adipose and the lymphatic impairment is associated with an M2 
polarization. Hence, the data presented here establish that the macrophages present in the 
mesentery tissue and/or on the walls of lymphatics are potent regulators of lymphatic 
vessel contractility under acute and chronic conditions of inflammation. 
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CHAPTER III 
ENDOTHELIAL NOS DEFICIENCY MEDIATES THE LOSS OF FLOW-
MEDIATED INHIBITION IN THORACIC DUCTS OF A HIGH FRUCTOSE 
FED RAT MODEL OF METABOLIC SYNDROME 
 
Overview 
Endothelial dysfunction is a hallmark of insulin resistance and the metabolic 
syndrome (MetSyn). We have previously demonstrated that stretch-mediated mesenteric 
lymphatic contractile parameters are impaired in MetSyn rats. Since thoracic duct 
lymphatics are more sensitive to flow response, we hypothesized that compromised 
thoracic duct endothelial function in the MetSyn animal will impact the shear sensitive 
thoracic duct function. To test our hypothesis, we used high fructose diet induced 
MetSyn rats and determined the changes in stretch- and flow-dependent mechanisms in 
their thoracic ducts using isobaric measurements. While thoracic ducts from rats with 
MetSyn did not show any significant changes in pressure-dependent isobaric 
measurements, the vessels displayed a lack of flow-mediated inhibition of contraction 
frequency and significantly altered shear sensitivity in vessel tone. Thoracic ducts from 
rats with MetSyn responded to the exogenous NO donor SNAP with reduced contraction 
frequency and reduced vessel tone suggesting a functional response to NO. Control rats 
treated with the NOS blocker LNAME had reduced flow sensitivity and closely 
resembled thoracic ducts from MetSyn rats. LNAME treatment of MetSyn thoracic ducts 
exacerbated the reduced flow-mediated inhibition. The ROS-scavenging agent TEMPOL 
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did not restore flow-mediated inhibition of contractions in MetSyn thoracic ducts. 
Western blots of thoracic ducts revealed a 50% reduction in the expression of eNOS in 
MetSyn group when compared to normal thoracic ducts. Thus our data provide the first 
evidence that MetSyn conditions diminish eNOS expression in thoracic duct 
endothelium, thereby affecting the flow-mediated functional characteristics of thoracic 
duct in MetSyn animals.  
 
Introduction 
The incidence of metabolic syndrome (MetSyn) has steadily risen, accompanying 
the rise of obesity (114). The MetSyn increases the risk of cardiovascular disease and 
type II diabetes mellitus (TIIDM). Approximately 85% of the patients with TIIDM also 
fall under the MetSyn spectrum (153). Diagnosis of the spectrum relies on the patient 
fulfilling 3 or more of the 5 criteria: systolic blood pressure >135mmHg, high waist 
circumference (>40in male, >35in female), hypertriglyceridemia  (>150mg/dl), 
hyperglycemia (>100mg/dl fasting glucose), and low high-density lipoprotein (<40mg/dl 
male, <35mg/dl female) (115). The MetSyn is also described as chronic yet is a sub-
clinical inflammatory state with elevated production of reactive oxygen species (ROS) 
and mitochondrial dysfunction. Elevations in ROS production by hyperglycemia and 
insulin resistance factor heavily into the observed hypertensive state, which is 
characterized by reduced NO bioavailability (16, 39, 161, 178, 278).  
Obesity is the most significant driver of the MetSyn state and is also linked to the 
development of diabetes and hypertension (194). Obesity has been described as a mild 
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edematous state and is a significant risk factor in the development of lymphedema 
following a mastectomy or other surgical cancer therapies (2, 67, 126, 166, 244). 
Lymphedema is a chronic and progressive disease, resulting from dysfunction of the 
lymphatic system that can arise due to genetic abnormalities (primary) or due to vessel 
damage or dysfunction (secondary) (254, 256). Morbidly obese patients are at high risk 
for developing spontaneous lymphedema, suggesting a role for lymphatic failure in 
obesity and MetSyn (12, 85, 87, 193, 208). However the regulatory mechanisms of 
lymphatic contractility under pathophysiological conditions, including MetSyn, have not 
been studied. 
Lymphatic function is critical to the uptake of macromolecules from the 
interstitial space and the maintenance of tissue fluid homeostasis. Lymph is carried 
through the lymphatic system through at least one node as it is returned to the blood 
supply at the juncture of the thoracic duct and the subclavian vein. Lymph must be 
transported against a net pressure gradient and the intrinsic lymphatic contractility and 
the presence of uni-directional valves is critical for this function (17, 352). Muscularized 
lymphatic vessels exhibit regular phasic contractions and tonic contractions to provide 
the necessary pressure stimulus to drive lymph flow (212). The lymphatic tissue is a 
unique muscle phenotype that has both contractile proteins found in cardiac and classical 
smooth muscle (226, 228). The lymphatic contraction cycle is described in a similar 
manner to the cardiac cycle and is regulated by both pressure and shear-dependent 
mechanisms (100, 101). Though specific pacemaker cells are not yet identified in 
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lymphatics, pacemaker activity drives lymphatic muscle depolarizations and calcium 
spikes which precede phasic contractions. 
Pacemaker activity is sensitive to stretch and frequency is positively correlated to 
increasing pressure (100, 318).  Lymphatic vessels, particularly the thoracic duct, are 
also regulated by sheer stress-induced NO production by the lymphatic endothelium 
(100). NO regulates lymphatic muscle relaxation through the activation of guanylate 
cyclase and increased cGMP levels (103). The actions of both PKG and PKA mediate 
the vasodilatory effects of NO stimulation (315). In response to imposed flow, or 
exogenous NO donors, thoracic duct frequency sharply falls and vessel tone decreases 
(100). Blockade with a NOS inhibitor abolishes this flow-mediated inhibition of thoracic 
duct contractility. To maintain proper fluid homeostasis, the lymphatic system must be 
able to relax when lymph formation and pressure gradients favor passive flow. Flow-
mediated inhibition reduces phasic contractility and reduces vessel tone thereby reducing 
resistance to flow. 
The high fructose fed rat model of MetSyn has also been demonstrated to have 
significant endothelial dysfunction in the blood vasculature (312). This has been linked 
to blunted vasodilatory responses due to the loss of tetrahydrobiopterin (BH4) (6, 279). 
BH4 is a critical co-factor for the production of NO and is sensitive to the redox stress of 
the cell (280). Elevated levels of ROS have been described in the high fructose fed rat 
model due to a significant increase in NADPH oxidase activity (66, 82, 303). Insulin is a 
key regulator of expression of eNOS and can increase NO production through 
phosphorylation at serine 1117 (338). Elevations in inflammatory cytokines can also 
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inhibit expression of eNOS and reduce NO production (16, 122) and the lymphatic 
vessels are exposed to much higher cytokine concentrations than blood endothelial cells 
(211). Hence in this study we have raised a question whether eNOS and/or ROS-
mediated NO mechanism(s) are impaired in the lymphatic endothelium, consequently 
affecting lymphatic function in MetSyn animals. 
We have previously reported that MLV exhibit diminished contractile activity in 
a high fructose model of MetSyn (357). Since the lymphatic thoracic duct is sensitive to 
the sheer-induced production of NO for proper contractility regulation, we have 
hypothesized that perturbation in thoracic duct endothelial cell activity in MetSyn 
animals will affect the flow-dependent NO mechanisms, thereby impairing the thoracic 
duct lymphatic function. We have utilized a high fructose fed rat model of MetSyn to 
address the role for NO in the regulation of thoracic ducts.  
 
Materials and Methods 
Animal Handling 
A total of forty-eight male Sprague Dawley rats were used in this study. Twenty-
three rats were given a high fructose feed (HFF) diet (60% fructose, ID.89247 Harlan 
Teklad®, 66% caloric content from fructose) for seven weeks to induce the MetSyn, 
while the remaining twenty-five animals were given standard rodent chow. Water and 
feed were available ad libitum except during pre-experiment (sixteen hour) fasting. 
Blood was collected in fasted (sixteen hour) rats via the lateral saphenous veins at the 
start and end of the seven-week diet period. The lower leg was shaved clean and the 
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lateral saphenous vein was punctured using a 27-gauge needle and blood was collected 
in a non-heparinized tube. Blood was allowed to clot for 1hr at room temperature and 
spun for ten minutes at 3,000g. Serum was then frozen and stored at -80°C. MetSyn was 
confirmed through evaluating triglyceride and insulin concentrations, assessed via 
commercially available kits (colorimetric kit Bioassays® ETGA-200, and an insulin 
ELISA kit Linco® EZMRI-13k, respectively). All animals were housed in a facility 
accredited by the Association for the Assessment and Accreditation of Laboratory 
Animal Care and maintained in accordance with the policies defined by the Public 
Health Service Policy for the Humane Care and Use of Laboratory Animals, the United 
States Department of Agriculture’s Animal Welfare Regulations and the Scott & White 
Animal Care and Use Committee. 
Rats fasted sixteen hours were anesthetized with Innovar-Vet (0.3 ml/kg I.M.), 
which is a combination of a droperidol-fentanyl solution (droperidol 20 mg/ml, fentanyl 
0.4 mg/ml), and diazepam (2.5 mg/kg IM). Once an anesthetic plane was reached, an 
incision was made through the chest ventral wall and the lymphatic thoracic duct was 
isolated and cut into two 1-cm segments. One segment was snap frozen in liquid 
nitrogen and stored at -80°C for protein collection. The remaining thoracic duct segment 
was maintained in albumin supplemented physiological saline solution (APSS, in mM: 
145.0 NaCl, 4.7 KCl, 2 CaCl2, 1.17 MgSO4, 1.2 NaH2PO4, 5.0 glucose, 2.0 sodium 
pyruvate, 0.02 EDTA and 3.0 3-(N-morpholino) propanesulfonic acid (MOPS) and 1% 
w/v bovine serum albumin) at pH 7.4 at 38°C. This thoracic duct segment was then 
cannulated onto carefully matched pipettes in a CH-1 chamber® (Living Systems) and 
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attached to independently adjustable pressure reservoirs. The thoracic duct was given 
thirty minutes to stabilize at an intramural pressure of 1cm H20 and spontaneous 
contractions were consistent. Experimental “n" values are as listed. Each thoracic duct 
was exposed to pressures of 1cm, 3cm, and 5cmH20 and 5-minute video recordings and 
diameter tracings were made at each intramural pressure. Nine control thoracic ducts and 
seven MetSyn thoracic ducts were exposed to 100µM SNAP at pressures of 1cm, 3cm, 
and 5cmH20. Sixteen control thoracic ducts and thirteen MetSyn thoracic ducts were set 
to a pressure of 3cmH20 and exposed to imposed flows by raising input and lowering 
output reservoirs such that transmural pressure was maintained at 3cm H20 (example; 
5cm input-2.5cm output is equivalent to F=1). These thoracic ducts were then returned to 
a pressure of 1cm H20 and were treated with either 1mM TEMPOL or 100µM LNAME 
and the pressure and flow responses repeated. Six control and six MetSyn thoracic ducts 
were exposed to 1mM TEMPOL for a twenty-minute equilibration and their responses to 
each pressure and flow recorded. Ten control and seven MetSyn thoracic ducts were 
incubated in 100µM LNAME for twenty minutes and their responses to each pressure 
and flow recorded.  Each experiment concluded with a twenty-minute equilibration in 
calcium-free APSS and maximal diameters at each pressure were determined for vessel 
tone calculation. Due to inherent variation between animals and vessels responses, tonic 
indexes were normalized to their level at a pressure of 3cmH20 prior to imposed flow. 
Isolated Vessel Video Analysis and Statistics 
Lymphatic diameter traces were made for each 5-min video with a vessel wall-
tracking program developed and provided by Dr. Michael Davis (53). Outer lymphatic 
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vessel diameters were tracked thirty times per second providing a trace of diameter 
changes throughout periods of systole and diastole. The following analogies to the 
cardiac pump parameters were derived: lymphatic tonic index, contraction amplitude, 
ejection fraction, contraction frequency, fraction pump flow, and systolic/diastolic 
diameters, as previously described (17). Lymphatic contractility is inhibited by flow as 
the vessel no longer needs to actively “pump” if pressure gradients favor positive flow. 
Contractions decrease average vessel diameter as a function of their frequency and 
ejection fraction and thus vessel resistance to flow will increase on the order of  (1/ 
radius^4), according to Poiseuille’s equation of resistance, as vessel length and viscosity 
are unchanged. To approximate the increase in vessel resistance, we took the total 
average diameter of the thoracic duct over that 5-min period and compared it to the 
average diastolic diameter (assumes a state of no contractions and no average radius 
change). The difference in true average diameter and diastolic diameter was halved to 
obtain the average radius change due to contractions and compared using 2-way analysis 
of variance (ANOVA) and reported as a mean radius change (in microns). As diastolic 
diameters were used, this calculation is independent of vessel tone and is dependent on 
frequency and the change in diameter during contraction. 
Statistics and Reporting 
Statistical significance was determined through 2-way ANOVA with Fisher’s 
post hoc analysis using the Statplus® (Analyst soft) statistical software package. Data 
are represented as means ± standard error of the means (SEM) and significance 
represented independently at each figure. 
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Protein Isolation and Western Blotting 
Snap frozen thoracic duct sections were thawed in 60µL of chilled 2x NuPage® 
sample buffer with protease inhibitor cocktail, phosphatase inhibitor cocktail, and 1x 
NuPage® reducing agent. Thoracic ducts were then sonicated for three minutes in a 
water bath sonicator and iced for five minutes. This process was repeated three times and 
then each sample was refrozen at -80°C. Samples were then thawed on ice and spun 
down at 1,000g to remove insoluble material and heated for ten minutes at 70°C, as per 
the manufacturer’s instructions. Thoracic duct samples were loaded in alternating 
fashion (n=6) in a 4-20% NuPage gel. Gels were run at 150v and then transferred to 
0.45-micron nitrocellulose overnight. Nitrocellulose membranes were stained with 
Ponceau S to ensure proper protein transfer and integrity. The blot was cut to allow 
simultaneous probing of eNOS and beta actin (βACT) and blocked in 5% milk for three 
hours. Mouse anti-rat βACT (Santa Cruz) and mouse anti- rat eNOS (BD Bioscience) 
were utilized at 1:5,000 and 1:1,000 dilutions, respectively, overnight at 4°C. Blots were 
rinsed with Tris-buffered saline (TBS, pH 7.4) and probed with goat anti-mouse 
antibody conjugated with horseradish peroxidase at 1:10,000 and 1:2,000 dilutions, 
respectively, for three hours at room temperature. Blots were imaged using SuperSignal 
West Dura Chemiluminescent Substrate® (Pierce) on an ImageQuant LAS-4000® (GE) 
System with linear scale adjustment to minimize background noise. Signal intensity was 
quantified using Image J and values normalized to βACT. The eNOS /βACT ratios were 
assessed with 1-way ANOVA for statistical significance. 
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Results 
Pressure- and Flow-Dependent Responses in MetSyn: Loss of Flow-Mediated Inhibition 
Thoracic ducts were isolated from each cohort and exposed to pressures of 1cm, 
3cm, and 5cm. There was no significant difference in diastolic diameter of thoracic ducts 
from the normal and MetSyn group. However, there was a large variability of thoracic 
duct diameters within both control and MetSyn cohorts with values ranging from 1100 
microns in diameter down to 650 microns. Such a large range in diameters will have 
significant effect on the magnitudes of stroke volume and lymph pump flow. As such, 
we have focused solely on the normalized contractility parameters, ejection fraction and 
fractional pump flow, to reduce the variability in volume-based metrics.  
There was a significant increase in lymphatic contraction frequency in the 
MetSyn thoracic ducts observed at a pressure of 5cmH2O (Figure 23). MetSyn thoracic 
ducts also displayed a significantly lower ejection fraction at pressures of 3cm and 
5cmH2O (Figure 23). Fractional pump flow values were not significantly affected at any 
pressure in the thoracic duct vessels in MetSyn group since the elevated frequency 
negated the decrease in ejection fraction (Figure 24). In addition MetSyn thoracic duct 
lymphatics did not exhibit a significant difference in tone at any pressure when 
compared to control vessels (Figure 24).  
The contraction frequency decreased sharply in control thoracic ducts in response 
to imposed flow as expected. In contrast, the imposed flow inhibition of contractility was 
blunted in the MetSyn thoracic ducts (Figure 25). The imposed flow inhibition of  
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Figure 23. Changes in contraction frequency and ejection fraction in thoracic ducts of 
rats with MetSyn. (A) Thoracic duct contractions per minute were counted in each 
pressure as described in the Methods section; (B) ejection fraction was calculated as 
described in the Methods section at each pressure. Data are presented as Mean ±	 SEM. 
N=23 MetSyn, 20 Control. 2-way ANOVA * denotes significance at p < 0.05 comparing 
MetSyn to control values at the same pressure   
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Figure 24. Changes in fractional pump flow and tonic index in thoracic ducts of rats with 
MetSyn. (A) Fractional pump flow and (B) vessel tone was calculated as described in the 
Methods section. Data are presented as Mean ±	 SEM. N=23 MetSyn, 20 Control. 2-way 
ANOVA * denotes significance at p < 0.05 comparing MetSyn to control values at the 
same pressure 
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Figure 25. Loss of flow-mediated inhibition of contractility in the thoracic ducts of rats 
with MetSyn. Thoracic duct vessels intramural pressure was maintained at 3cmH2O. 
Vessel contraction (A) and ejection fraction (B) was counted and calculated as described 
in the Methods section, at different imposed flow conditions.  Data are presented as 
Mean ±	 SEM. N=13 MetSyn, 16 Control. 2-way ANOVA * denotes significance at p < 
0.05 comparing MetSyn to control values at the same pressure 
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contractility was blunted in the MetSyn thoracic ducts as contraction frequency was 
significantly higher than controls at each flow. Thoracic duct ejection fraction was not 
significantly different between control and MetSyn thoracic ducts, however ejection 
fractions rose with increasing flow gradients (Figure 25).  The increased contraction 
frequency significantly increased the MetSyn thoracic duct resistance to flow at 3cm and 
5cmH20 (Figure 26). MetSyn thoracic ducts had significantly higher normalized tone at 
flow of 5cmH20 and had a significantly different flow*tone response (Figure 27). Linear 
regression analysis of normalized tone revealed a significant difference in the interaction 
between flow and thoracic duct tone. Control tone decreased (y = -0.02x) with imposed 
flow while MetSyn thoracic ducts demonstrated a slight constriction (y = 0.05x) in 
response to imposed flow (Figure 27).  
Lymphatic Thoracic Ducts from MetSyn Rats are Responsive to NO 
 Since thoracic ducts from MetSyn rats displayed a blunted flow-mediated 
inhibition, we determined their sensitivity with exogenous NO. Vessels were exposed to 
the NO SNAP at 100µM to assess lymphatic muscle response to NO at each pressure. 
Exposure to 100µM SNAP significantly reduced lymphatic contraction frequency in 
both control and MetSyn vessels (Figure 28). In agreement with our findings during 
imposed flow, ejection fraction was not significantly reduced in control thoracic ducts 
after exposure to 100µM SNAP. However, we found that ejection fraction was 
significantly reduced at a pressure of 3cmH20 in MetSyn thoracic ducts exposed to 
100µM SNAP. Additionally, 100µM SNAP significantly reduced vessel tone in control 
thoracic ducts at each experimental pressure. In contrast, MetSyn tone was significantly  
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Figure 26. Loss of flow-mediated inhibition in MetSyn thoracic ducts increases vessel 
resistance to flow as a function of average vessel radius. The vessel resistance was 
calculated as described in the Methods section. Data are presented as Mean ±	 SEM. 
N=13 MetSyn, 16 Control. 2-way ANOVA * denotes significance at p < 0.05 comparing 
MetSyn to control values at the same pressure 
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Figure 27. Loss of flow-mediated inhibition of vessel tone in MetSyn thoracic ducts. 
Vessel tone in response to flow (A) and the liner regression of imposed flow and tone 
(B) was calculated as described in the Methods section. Data are presented as Mean ±	 
SEM. N=13 MetSyn, 16 Control. 2-way ANOVA * denotes significance at p < 0.05 
comparing MetSyn to control  
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Figure 28. Contraction frequency and ejection fraction in thoracic ducts in response to 
100uM SNAP. (A) contraction frequency was counted as contractions per minute for 
each pressure; (B) ejection fraction was calculated as described in the Methods section. 
Data are presented as Mean ±	 SEM. N=7 MetSyn, 9 Control. 2-way ANOVA * denotes 
significance at p < 0.05, ^ denotes significance at 0.05 < p < 0.1 comparing within the 
cohort 
 
 
 
0.!
5.!
10.!
15.!
20.!
25.!
30.!
P=1! P=3! P=5!
Co
nt
ra
cti
on
 pe
r M
inu
te!
Intramural Pressure!
MetSyn Frequency Response to 100uM SNAP!
Control!
CNT SNAP!
MetSyn!
MetSyn SNAP!
* 
* 
* 
* 
A
0 
0.1 
0.2 
0.3 
0.4 
0.5 
0.6 
0.7 
P=1 P=3 P=5 
Ej
ec
tio
n 
Fr
ac
tio
n 
Intramural Pressure 
MetSyn Ejection Fraction Response to 100uM SNAP 
Control 
CNT SNAP 
MetSyn 
MetSyn SNAP 
* 
B 
  
98 
lowered by SNAP only at a pressure of 1cm but was not statistically different at 
pressures of 3cm or 5cmH20 (Figure 29). However, the cohort of MetSyn thoracic ducts 
treated with SNAP exhibited significantly lower tone basally compared to control vessel 
tone at pressures of 3cm and 5cmH20, and this may have masked the SNAP response 
(Figure 29). TEMPOL Did Not Restore Flow-Mediated Inhibition 
 ROS are known to reduce NO bioavailability and ROS have been implicated in 
endothelial dysfunction. We used 1mM TEMPOL to block the effect of ROS, in order to 
assess the role of NO bioavailability in the MetSyn thoracic ducts at each pressure and 
flow. Contraction frequency and ejection fraction were not affected by 1mM TEMPOL 
in both control and MetSyn vessels under any experimental pressure or flow condition 
(Figure 30). 
Control Thoracic Ducts Gain MetSyn Phenotype by Exposure to LNAME 
NO is a potent regulator of lymphatic contractility and the thoracic duct is 
specifically sensitive to flow-mediated NO production. We wanted to determine the role 
of NO production in MetSyn thoracic duct contractility regulation in response to both 
pressure and imposed flow conditions. LNAME (100µM) significantly increased 
contraction frequency in control thoracic ducts at a pressure of 5cmH2O and trended 
higher (0.05 < p < 0.1) at pressures of 1cm and 3cmH2O (Figure 31). Interestingly, 
100µM LNAME also significantly increased contraction frequency of MetSyn vessels at 
each pressure. However, ejection fraction of control and MetSyn vessels was unaffected 
by LNAME except for a reduction observed in control vessels at a pressure of 1cmH2O 
(Figure 31). While vessel tone was increased in response to LNAME in control vessels 
  
99 
  
Figure 29. Exogenous NO reduces vessel tone in both control and MetSyn thoracic duct. 
Vessel tone was calculated as described in the Methods section. Data are presented as 
Mean ±	 SEM. N=7 MetSyn, 9 Control. 2-way ANOVA * denotes significance at p < 
0.05, ^ denotes significance at 0.05 < p < 0.1 comparing within the cohort, # denotes 
significance at p < 0.05, “ denotes significance at 0.05 < p < 0.1 comparing across 
cohorts
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Figure 30. Inhibition of ROS did not restore flow-mediated inhibition in MetSyn 
thoracic duct. Thoracic ducts (TD) vessel contractile frequency in the presence of 1mM 
TEMPOL was measured at each pressure (A) and under different flow conditions (B). 
Data are presented as Mean ±	 SEM. N=6 MetSyn, 6 Control. 2-way ANOVA * denotes 
significance at p < 0.05, ^ denotes significance at 0.05 < p < 0.1 comparing within the 
cohort 
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Figure 31. Changes in contraction frequency and ejection fraction of control and MetSyn 
thoracic ducts in the presence of LNAME. Thoracic ducts (TD) were equilibrated for 
twenty minutes in 100µM LNAME and their responses to pressure were recorded and 
analyzed for contraction frequency (Top Panel) and ejection fraction (Bottom Panel). 
Data are presented as Mean ±	 SEM. N=7 MetSyn (MS), 10 Control (CNT). 2-way 
ANOVA * denotes significance at p < 0.05, ^ denotes significance at 0.05 < p < 0.1 
comparing within the cohort 
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at pressures of 3cm and 5cmH2O, LNAME had no significant effect on vessel tone in 
MetSyn thoracic ducts (Figure 32). As described earlier, control frequency decreases 
with imposed flow and this reduction is blunted in MetSyn vessels. MetSyn thoracic 
ducts had significantly higher contraction frequency at flows 1cm, 3cm, and trended 
higher at 5cmH2O flow (p<0.1; Figure 33). LNAME significantly increased contraction 
frequency in control vessels at flows of 1cm and 3cmH2O. Control thoracic ducts treated 
with LNAME were not statistically different than the contraction frequency response in 
MetSyn thoracic ducts. As expected, LNAME exacerbated the loss of flow-mediated 
inhibition phenotype observed in MetSyn thoracic ducts. LNAME significantly 
increased contraction frequency in MetSyn thoracic duct at each imposed flow. In 
agreement with our SNAP response, LNAME did not affect ejection fraction in either 
control or MetSyn thoracic ducts (Figure 33). The rise in contraction frequency by  
LNAME increased vessel resistance to flow as demonstrated by the higher change in 
radius as a result of spontaneous contractions (Figure 34). LNAME also increased 
normalized tone in control thoracic ducts at flows of 1cm and 3cmH2O, whereas, there 
was no significant effect observed in MetSyn thoracic ducts (Figure 34). Table 6 
summarizes the contraction parameters from each treatment cohort and their combined 
responses. 
ENOS Insufficiency in the Thoracic Ducts Isolated from MetSyn Rats 
Thoracic ducts were snap frozen in liquid nitrogen and stored at -80C. Protein 
was harvested under denaturing conditions and utilized for western blots. Protein from 
six control and six MetSyn thoracic ducts was loaded in alternating fashion and probed  
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Figure 32. Changes in vessel tone in the control and MetSyn thoracic ducts in the 
presence of LNAME. Thoracic ducts (TD) were equilibrated with 100µM LNAME for 
twenty minutes and their functional responses to pressure and flow were determined. 
Vessel tone was calculated as described in the Methods section. Data are presented as 
Mean ±	 SEM. N=7 MetSyn (MS), 10 Control (CNT). 2-way ANOVA * denotes 
significance at p < 0.05, ^ denotes significance at 0.05 < p < 0.1 comparing within the 
cohort 
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Figure 33. Changes in contraction frequency and ejection fraction in both control and 
MetSyn thoracic ducts in the presence of LNAME. Thoracic ducts (TD) were 
equilibrated with 100µM LNAME for twenty minutes and their functional responses to 
pressure and flow were reassessed as described in the Methods section. Data are 
presented as Mean ±	 SEM. N=7 MetSyn (MS), 10 Control (CNT). 2-way ANOVA * 
denotes significance at p < 0.05, ^ denotes significance at 0.05 < p < 0.1 comparing 
within the cohort, # denotes significance at p < 0.05, “ denotes significance at 0.05 < p < 
0.1 comparing across cohorts 
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Figure 34. Changes in vessel resistance and tone under different flow conditions in 
control and MetSyn groups in the presence of LNAME (L). Vessel resistance (Top 
panel) and tone (bottom panel) was calculated as described in the Methods section. Data 
are presented as Mean ±	 SEM. N=7 MetSyn (MS), 10 Control (CNT). 2-way ANOVA * 
denotes significance at p < 0.05, ^ denotes significance at 0.05 < p < 0.1 comparing 
within the cohort 
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Table 6. Summary of contractile parameters for MetSyn and control thoracic ducts 
 
Data are presented as means ± SEM for outer diastolic diameter, lymphatic contraction 
frequency, ejection fraction, and tonic index. Due to inherit variability in contraction, 
each treatment (SNAP, TEMPOL, LNAME) was compared with the APSS values for 
those specific vessels in determining functional response.  
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for eNOS and βAct. One MetSyn sample was excluded from quantitative analysis due to 
an aberrant βAct signal. We normalized eNOS signal intensity to βAct and found a 
consistent and significant reduction in eNOS expression in the MetSyn thoracic ducts 
(Figure 35). 
 
Discussion 
The results presented in this study demonstrate the first evidence that lymphatic 
ducts isolated from rats with MetSyn exhibit a blunted flow-mediated inhibition of 
contractility that significantly impaired their conduit contractility regulation. However, 
MetSyn thoracic ducts were sensitive to both exogenous NO supplied by SNAP and 
NOS inhibition when treated with LNAME. This demonstrates that the NO sensitivity 
and regulation in the lymphatic muscle cells and pacemaker cells is functional and 
suggests an inadequate production of NO by the endothelial cells. Control vessels also 
demonstrated a blunted flow-mediated inhibition of contractility when treated with 
LNAME. Scavenging of ROS with TEMPOL did not restore flow-mediated inhibition 
nor did it affect lymphatic vessel contractility. Western blots revealed a significant loss 
of eNOS expression by the MetSyn thoracic duct and may account for the blunted flow-
mediated dysfunction. These observations have been summarized into the working 
model for lymphatic thoracic duct dysfunction in MetSyn (Figure 36). 
 Our results provide further evidence for the role of NO production in response to 
sheer stress as a critical regulator of lymphatic contractility. Imposed flow causes a sharp  
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Figure 35. Reduced expression of eNOS in thoracic ducts isolated from MetSyn rats. 
Protein was collected from thoracic ducts isolated from control and MetSyn rats and 
used for western blots to assess eNOS expression. Beta actin (βAct) was used as a 
loading control. Top Panel: a representative western bot; C-control sample, M-MetSyn 
sample, O-omitted sample in the analysis due to low amount of protein loading. Bottom 
Panel: Quantitative analysis of eNOS expression. The eNOS/ βAct ratios were 
normalized to control values. The values obtained from 3 different blots were used for 
the analysis. Data are presented as Mean ±	 SEM. N=5 MetSyn, 6 Control. 2-way 
ANOVA * denotes significance at p < 0.05 
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Figure 36. Working model of thoracic duct dysfunction in the metabolic syndrome. Loss 
of flow-mediated inhibition appears to be partly mediated through reduced eNOS 
expression. Loss of insulin signaling, inflammatory cytokines, and oxidative stress can 
each contribute to lowered eNOS expression. Despite the loss in eNOS signaling, 
MetSyn thoracic ducts appear to be highly sensitive to NO. Lymphatic thoracic ducts 
express a high level of PKG1b that is less sensitive to elevated cGMP than PKG1a. An 
adaptive response could include increased expression of PKG1a in the MetSyn thoracic 
ducts. Other unknown factors are also at play as lymphatic vessel dysfunction is 
exacerbated by NOS inhibition with LNAME. Control vessels take on a MetSyn 
phenotype characterized by blunted flow-mediated inhibition of contraction frequency 
when treated with LNAME, but contraction frequency in MetSyn thoracic ducts is still 
significantly higher, suggesting a gain of function that increases pacemaker cell 
depolarization. 
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reduction in contraction frequency in control thoracic ducts and this response was 
blunted in the MetSyn. Others have demonstrated a critical for NO in the shear-induced 
relaxation of the lymphatic pump and vessel tone (102, 317, 322). NO stimulates 
guanylate cyclase and increases cGMP levels that result in both activation of PKA and 
PKG that hyperpolarize the lymphatic muscle (103, 315). Poor endothelial dysfunction 
has been consistently reported in the blood vasculature in both rodent models and human 
studies (21, 34, 46, 194, 294, 303, 347). Thoracic ducts isolated from MetSyn rats 
displayed blunted flow-mediated inhibition, as contraction frequency was significantly 
higher than control thoracic ducts. Under most conditions, the lymphatic contractility is 
required for proper lymphatic transport of fluid and macromolecules from the interstitial 
space. However, if conditions favor passive flow, these phasic contractions increase 
vessel resistance to flow as a function of decreased vessel diameter. The sustained 
contractility in the MetSyn thoracic ducts significantly increases vessel resistance to 
flow by reducing average vessels diameter. The post-prandial lymphagogic effect is one 
such event where lymph flow increases four to six fold over fasting levels as dietary fat 
is packaged into chylomicrons and transported through the lymphatic system (28, 182, 
284, 301). Poor dilation and inhibition of contractility will increase the resistance to 
lymph flow, driven in part by increased filtration of intestinal capillaries and the 
peristaltic action of the intestine. We have previously reported impairment in the MLV 
contractility in an identical high fructose fed rat model of MetSyn (357). In that study rat 
MLV dysfunction was correlated with low contraction frequency and similar results 
were described in mouse models of MetSyn (25, 262, 330, 357). In contrast, MetSyn 
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thoracic ducts have an elevated contraction frequency and this is likely due to poor NO 
bioavailability.  
Under isobaric conditions the spontaneous contractions in the thoracic duct are 
sufficient to propel fluid and increase NO production in a self-regulatory manner (104). 
Inhibition of eNOS under non-flow conditions increased contraction frequency and our 
data supports this finding. However, MetSyn thoracic ducts also increased their 
contraction frequency in response to LNAME. This could be an adaptive mechanism in 
response to the poor functioning smaller pressure-sensitive lymphatic (357) collecting 
vessels, as previously reported (357). Another explanation would be that, in addition to 
losing NO production, there is likely an elevated contractile stimulus that results in 
hyperactivity of the pacemaker cells. Additional studies are warranted to support this 
notion. 
Flow-mediated inhibition was originally described as a sharp reduction in 
contraction frequency, reduced vessel tone, and reduced ejection fraction (102). 
Interestingly, we observed a positive correlation between ejection fraction and imposed 
flow. Previous reports have suggested that ejection fraction decreases over time in 
response to flow through NO production (102). In our study, control rat thoracic duct 
ejection fractions were not consistently changed by either SNAP or LNAME. A 
significant reduction in ejection fraction was noted with 100µM LNAME at an 
intramural pressure of 1cmH2O. We surmise that the reduction of ejection fraction in 
response to LNAME is likely due to the doubling of contraction frequency and reduction 
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in calcium store uptake, since calcium-induced calcium release from the sarcoplasmic 
reticulum is critical for contraction amplitude and ejection fraction (319).  
Animal age and weight are both potentially responsible for the differences 
observed in the thoracic duct ejection fraction in response to flow between our study and 
previous reports (100-102). A previous study has identified elevated ROS production in 
the mesenteric vessels of aged animals, which have lymphatic contractility impairments 
as well. We did not see an acute effect of the ROS scavenging molecule TEMPOL, 
although it was a very acute application and likely insufficient to alter the cellular 
proteins that are sensitive to chronic oxidative stress. Additionally, elevated ROS 
production is linked to reduced contraction frequency (298, 353, 356) and we have 
reported an elevated contractile frequency in the thoracic ducts of MetSyn rats. 
Superoxide readily combines with NO to create peroxynitrite and it is possible that the 
elevated production of ROS is insufficient to reduce lymphatic thoracic duct contractility 
as evidenced by an appreciable role of endogenous NO production. Additionally, the 
short time frame of TEMPOL exposure may be insufficient to restore thoracic duct 
levels of BH4, which is a critical regulator of eNOS activity (29, 39, 178). 
We have demonstrated a significant reduction in the expression eNOS that 
supports our findings of reduced flow-mediated inhibition response. Endothelial 
dysfunction is multifaceted and loss of eNOS expression is just one aspect of this 
phenomenon. Phosphorylation of eNOS at serine 1177, the availability of L-arginine 
substrate for key enzymes, the presence of critical cofactors such as BH4, and the 
oxidative stress of the cell all feed into endothelial dysfunction (92). Reduced eNOS 
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expression is commonly observed in models of obesity and diabetes, and can partly be 
explained through insulin resistance and the chronic inflammatory state. As lymph 
drains the interstitial fluid, it hosts a concentrated milieu of inflammatory cytokines as 
compared to the blood (211). Inflammatory cytokines (131, 135-137) and elevated fatty 
acids reduce insulin sensitivity (292) and promote endothelial dysfunction (109, 122, 
274). Studies in the blood vasculature have linked endothelial dysfunction with insulin 
resistance, and therapies that increase insulin resistance often restore endothelial 
function (21, 34, 161, 232). The role of insulin on lymphatic endothelial function is not 
well described despite its presence in common cell culture media formulations used for 
lymphatic endothelial cell cultures. In the blood vasculature, insulin increases eNOS 
expression and activates eNOS through phosphorylation (70, 92, 217).  Rosiglitazone 
belongs to the thiazolidinedione class of drugs that increase insulin sensitivity and, as a 
consequence, endothelial function, through activation of PPARγ. However, 
thiazolidinedione treatment has also been linked with weight gain, fluid retention, mild 
edema, and increased risk of cardiovascular pulmonary edema, suggesting that it may 
have off target consequences on lymphatic function (169). Interestingly, ZDF rats were 
previously described to have poor lymphatic clearance of tissue macromolecules and 
blood vascular dysfunction (45). In that study, treatment with rosiglitazone restored 
capillary function but did not restore lymphatic function (45).  
Additionally, the adipose tissue has recently been described as a potent producer 
of vasodilators that are reduced in models of adipose tissue inflammation (110, 210, 
240). Lymphatic tissues have a unique association with adipose tissue that has yet to be 
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fully described and often adipocytes can’t be completely dissociated from the thoracic 
duct during isolation without damaging the vessel. While the high fructose fed MetSyn 
model does not display overt obesity, we have previously reported perivascular adipose 
accumulation in this model (357) and the prototypical adipose depots are chronically 
inflamed (276). However, we did not observe an increase in vessel tone in the MetSyn 
thoracic ducts. The effects of the adipose-derived relaxing factors and stimulating factors 
on lymphatic contractility have not been explored in regards to the duality of lymphatic 
contractility.  
Loss of NO through abrogation of eNOS expression does not completely explain 
thoracic duct dysfunction in the MetSyn rats. Control thoracic ducts treated with 
LNAME displayed similar frequencies as MetSyn thoracic ducts without LNAME. 
However, LNAME-treated MetSyn thoracic ducts demonstrated further increased 
contraction frequency under both pressure and imposed flow. In addition, MetSyn 
thoracic ducts displayed a very unique constriction in response to flow, but MetSyn 
thoracic duct tone was not significantly affected by LNAME in contrast to the significant 
increase in tone in control thoracic ducts. This suggests that endogenous production of 
NO and increased NO sensitivity in the MetSyn thoracic duct are able to mask a gain of 
function that increases pacemaker activation and uncouples endogenous NO production 
from vessel tone. It is likely that multiple pathways drive the thoracic duct dysfunction, 
including hypersensitivity to NO, reduced NO production by the endothelium, and 
increased activation of the pacemaker cell(s). Many questions arise in response to the 
observations here. Is the reduced eNOS expression due to insulin resistance or elevated 
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inflammatory cytokine loads? How do insulin and glucose concentrations regulate 
lymphatic endothelial eNOS and redox potential? Is there an elevated fatty acid flux into 
the lymphatics that reduces insulin sensitivity? In vitro analysis using tissue specific 
lymphatic cells holds promise for clarification of these issues. Additionally, other 
mechanisms of lymphatic contractility regulation must be explored and more studies are 
needed to fully describe lymphatic endothelial dysfunction in the MetSyn. 
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CHAPTER IV 
DISCUSSION: SUMMARY AND CONCLUSIONS 
 
Implications 
The MetSyn is a serious disease that underscores a significant risk for 
cardiovascular disease due to the presence of multiple metabolic impairments. The 
syndrome has risen in association with both type II diabetes and obesity as a result of 
poor diet and a sedentary lifestyle and afflicts over 34% of the population (237). 
Exercise and proper nutrition is the strongest therapy and preventative measure for 
MetSyn, which has reached into the hundreds of millions for estimated annual medical 
care costs (89). Obesity is the strongest driver of the MetSyn phenotype in humans and 
up to 85% of type II diabetic individuals are diagnosed with the MetSyn (153). The 
morbidity of these interrelated diseases has drawn significant focus on the drivers of 
pathologies. Great strides have been made in uncovering the roles of adipose 
dysfunction, insulin resistance, and endothelial dysfunction that directly affect the risk of 
cardiovascular disease and mortality in these patients. However, lymphatic function is 
often overlooked in these disease states, despite it role in maintenance of tissue fluid and 
macromolecule homeostasis and immunosurveillance.  
Obesity is often characterized as a mild edematous state and has been historically 
known as a critical risk factor for the development of lymphedema following cancer 
surgeries and nodal biopsies (2, 126, 166, 324). There has also been evidence of poor 
macromolecule clearance from the adipose tissue in obesity and diabetes (9). Obese 
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humans often exhibit increased skin infections, surgical site infections, and delayed 
immune responses (139). Similar observations have been reported in obese rodent 
models and there is a known impairment in both the innate and adaptive cellular 
compartments (65, 185, 195, 287, 295). In this study, we have demonstrated that 
activation of macrophages, which are important mediators of tissue homeostasis and 
inflammation, is associated with impaired lymphatic contractility of the MetSyn animals 
in the mesenteric bed. Each of these observations suggests a connection between the 
MetSyn and lymphatic dysfunction. This connection has recently crystallized with the 
observation of development of spontaneous lymphedema in the morbidly obese 
population (12, 41, 81, 87, 193, 208, 214). Up to 80% of the morbidly obese patients can 
expect to develop massive localized lymphedema (MLL) at some point in their life. This 
form of lymphedema is associated with severe accumulation of interstitial fluid that 
progresses into a large fibrotic mass that resembles a sarcoma (41, 81, 111). MLL 
impairs the patient’s ability to exercise and severely reduces their quality of life. 
Resolution from surgical procedures to remove the associated mass of fatty and fibrotic 
tissue that develops in MLL is temporary and the lymphedema will return if the 
underlying metabolic dysfunction is not addressed (85). Additionally, human type II 
diabetes patients were found to have aberrant lymphangiogenesis in the skin and a highly 
inflammatory expression profile (118). Elevated lymphangiogenesis and inflammation 
has been described in rodent models of colitis that are associated with poor lymph 
function (3, 47). Interestingly, genetic models that have poor lymphatic vessel formation 
develop spontaneous obesity in adulthood (123, 125). Lymphedema is a chronic and 
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progressive disease that causes persistent quality of life issues and is a major health 
concern with the rising incidence of MetSyn. 
The lymphatic system serves critical functions in the maintenance of tissue and 
fluid homeostasis while also directing immune responses. Contrary to popular opinion, 
the lymphatic system is not a passive conduit from which lymph “drains” from the tissue 
and it requires the coordinative action of phasic contractions and uni-directional valves 
to drive lymph flow (352). In contrast to the heart, the lymphatic system is not a 
circuitous system and mammals lack the lymphatic hearts found in lower organisms.  
Instead, the lymphatic vessels themselves are able to drive lymph against a pressure 
gradient through both phasic and tonic contractions of muscularized collecting lymphatic 
vessels (352). The action of extrinsic forces such as tissue compression, inspiration, or 
muscle contractions in addition to the intrinsic pumping of the lymphatic system drive 
lymph from the periphery centripetally back to the blood circulation at the junction of 
the subclavian vein and the thoracic duct.  
The smallest functional contracting unit of the lymphatic system is called the 
lymphangion and it defines the contracting vessels both upstream and downstream of a 
uni-directional valve (212). The contractility of the lymphangion is regulated by physical 
stimuli such as stretch and flow (100), but contractility is under control of both 
inflammatory and neural interactions (318, 320). The phasic contractility of the 
lymphatic system bears similarity to that of the heart and similar contractile parameters, 
while also displaying tonic constrictions that are typical of smooth muscle in the blood 
vasculature. Lymphatic muscle expresses elements of both the classic smooth muscle 
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contractile machinery and cardiac muscle proteins but the mechanisms regulating the 
two pathways are still unclear (226, 228). Phasic contractions drive the necessary 
pressure gradients to propel fluid downstream and this is critical to lymphatic function 
(17). For proper lymph transport, lymphatic vessels must also be able to regulate conduit 
function, when conditions favor passive lymph flow, through the regulation of tonic 
contractions. The data presented in this dissertation have provided consistent and broad 
evidence to support the hypothesis that lymphatic function is impaired in the MetSyn 
and have described novel mechanisms modulating MLV and lymphatic thoracic duct 
dysfunction in a rodent model of MetSyn. 
Inhibition of the lymphatic pump under inflammatory conditions has been 
previously described in multiple disease states (152, 340) and loosely associated with 
myeloid cell activation (120, 164, 187). However, the majority of these studies rely on 
lymphatic clearance of dyes or tracers from the interstitial space to describe lymphatic 
dysfunction (164). Liao et al. have utilized intravital microscopy to visualize lymphatic 
contractility in vivo in response to oxalozone-induced inflammation and in response to 
activated monocytes (187). These studies provide a great display of lymphatic function 
in disease states but are limited by the influence of multiple confounding factors, such as 
the effect of extrinsic forces driving lymph, uncontrolled tissue pressures that are often 
affected by injection of the dye upstream of the imaging field, unknown contractile 
regulation by cells and contents within the lymph, and the identity of the local 
inflammatory cells in the vicinity of the vessel.  
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We have utilized an isolated lymphatic vessel preparation that controls 
transmural pressure and focuses on the specific contractility of a single lymphangion. 
This provides the necessary understanding of the lymphatic contraction regulation 
independent of tissue factors or forces. Our previous study was the first such example of 
lymphatic dysfunction in the MetSyn state (357) and similar observations have now been 
made in mouse models of MetSyn (25, 262, 330). Interestingly, we have observed 
similar contractility impairment as described in the work published by Liao et al. in that 
two different phenotypes of lymphatic contractility were displayed in inflamed vessels 
(187). We observed a MetSyn MLV phenotype characterized by low frequency and low 
ejection fraction, which suggests an overproduction of NO by the resident macrophage 
population (187), and it was the dominant phenotype in our previous study (357). In 
addition, we have also described a high frequency low ejection fraction phenotype in the 
MLV of rats with MetSyn, and both of these contractile patterns have been observed 
previously (187). This suggests that there is likely a separate mechanism by which 
activated macrophages or monocytes can regulate lymphatic function into a low or high 
contractility phenotype.  
The role of NO in the regulation and inhibition of lymphatic contractility has 
been well described (26, 27, 102, 104, 264, 267, 281, 315, 323). Substance P (SP) is 
known to cause a significant increase in contraction frequency and reduction in ejection 
fraction in addition to a modest tone change at low doses (7, 55).  Macrophages and 
eosinophils are both sources of SP in the periphery and its production may underlie the 
hyper-contractility phenotype. SP is also involved in the inflammation and pathogenesis 
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of obesity and its production by innate immune cells could play a role in the alterations 
of lymphatic contractility (97, 113, 156). 
This dissertation has provided critical evidence to suggest that the macrophage 
populations that reside within the wall of the collecting lymphatic vessels must be 
discussed in regards to the contractility of the lymphatic vessels under disease and 
physiological states. We provide evidence of isolated MLV contractility impairment in 
both chronic (MetSyn) and acute (LPS-induced peritonitis) inflammatory states. In each 
situation we found an alteration in the macrophage population that resides within the 
tissue and along the collecting lymphatic vessel. Specifically, we have identified two 
major macrophage polarizations that are associated with lymphatic collecting vessel 
dysfunction. The LPS-induced peritonitis model includes massive macrophage 
accumulation in the mesenteric neurovascular bundles and the perivascular adipose 
tissue. We found that lymphatic vessels demonstrated extreme densities of macrophages 
in association with the MLV that suggests a basal chemoattractant index. This could be 
due to innate production of chemoattractant proteins, such as chemokine (C-C motif) 
ligand 2(CCL2) (155, 245, 263), or “leak” from the lymph (48), which is a concentrated 
source of cytokines and chemokines (211). Our data demonstrate a role for M2 
macrophages, characterized as CD163+CD206+, in the maintenance of the normal 
mesenteric tissue function. Chronic injections of LPS into the peritoneum increased this 
macrophage pool two fold and they exhibited morphological characteristics of 
activation, e.g., appearance of dendrites and spines. However, LPS also induced a 
significant increase in the presence of CD163-CD206+ cells that displayed a different 
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morphology. It is likely these CD163-CD206+ cells represent the quasi-inflammatory 
M2b macrophage phenotype that is induced by TLR activation and immune complexes 
(11, 165, 200, 218, 219). Both of these cells types were significantly elevated in the 
mesenteric perivascular tissue and in association with the MLV. MLVs isolated from the 
LPS-injected rats had critically reduced lymph pump function. Four of seven vessels 
used in the study lacked any phasic contractions at any pressure and the remaining three 
exhibited poor contractility. It is likely that excess NO production by these macrophages 
is the critical element in the mediating this dysfunction.  
We have also provided new evidence to support the hypothesis that the lymphatic 
vessel provides a stromal environment for resident macrophages through production of 
the MCSF and GMCSF. These two molecules are critical to monocyte/macrophage 
maturation and polarization. Loss of MCSF signaling significantly reduces the number 
of macrophages and the MCSF/GMCSF ratio is critical to the polarization of the M1 and 
M2 phenotype. Cultured mLMCS and mLECs both expressed high levels of MCSF and 
GMSCF in the presence of LPS.  We also found a large increase in the production of 
CCL2 and CCL1 in the LPS-stimulated mLECs. CCL2 is critical to monocyte 
recruitment and is a classic marker of tissue inflammation. Interestingly, CCL1 has been 
described as a potent activator of the M2b macrophage phenotype and critical for 
maintenance of that polarization state (11).  CCL1 production by the lymphatic muscle 
and endothelium may regulate the CD163-CD206+ M2b macrophages identified in the 
LPS-induced peritonitis model. mLECs were unique in that GMCSF expression was 
almost non-existent in the basal state despite high MCSF expression. However, GMCSF 
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exhibited a massive increase in response to LPS and could act as an inflammatory 
switch.  
GMCSF is commonly used to induce the M1 macrophage polarization with in 
vitro systems. We found a significant skewing of the adipose tissue macrophages to an 
M1 polarization in the MetSyn rats as evidenced by a significant increase of 
CD163+MHCII+ cells. This fits well with the current paradigm of a M1 shift in the 
adipose tissue in conditions of obesity and MetSyn (195). The dysfunction of the 
intrinsic lymphatic pump likely contributes to the mild edematous state that accompanies 
obesity, the increased risk of skin infections, and the lymphedema observed in the 
morbidly obese population. Macrophage activation and polarization will have critical 
effects on lymphatic collecting vessel function. Suppression of the lymphatic pump will 
result in edema, however this association may have been selected as a mechanism to 
prevent dissemination of infection through the lymphatic system (187, 254, 255). 
Increased dietary endotoxin is a driver of the MetSyn phenotype and inflammation. 
Conditions for excess dietary endotoxin absorption (35, 72, 79, 105, 116, 328) have been 
described and present a possible scenario for the alterations in lymphatic vessel function 
and macrophage polarization observed in the MetSyn rats (35, 79). 
 For proper lymphatic function, vessels must also be able to regulate their 
function as a conduit system when conditions favor passive flow. The lymphatic system 
displays keen sheer sensitivity that is mediated primarily by NO. Endothelial 
dysfunction is a hallmark of the MetSyn and contributes to the hypertension associated 
with the disease state (21, 46, 274, 294, 305). Endothelial dysfunction refers to the 
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inability of endothelial cells to produce the appropriate level of vasodilatory agents 
particularly NO. Poor NO bioavailability is responsible for the hypertension observed in 
many obese and diabetic rodent models.  
The lymphatic thoracic duct is the largest lymphatic vessel in the body and sheer 
stress in response to flow is a critical regulator of its contractility (101). Flow-mediated 
inhibition of contractility has been well documented in the lymphatic thoracic duct 
(100). However, the presence of endothelial dysfunction and the flow-mediated 
inhibition of contractility response in the lymphatic vasculature have been ignored in 
MetSyn research, despite the evidence for poor lymph function. We utilized a high 
fructose fed rat model of MetSyn and demonstrated a significant reduction in the flow-
mediated inhibition of contractility. Thoracic ducts from MetSyn rats also appeared to 
have elevated NO sensitivity despite the poor response to flow. This suggested a reduced 
bioavailability of NO in the MetSyn thoracic duct. Western blots for eNOS demonstrated 
a sharp reduction (60%) in eNOS expression in MetSyn thoracic ducts. This supported 
our finding of blunted flow-mediated inhibition of contractility and suggests that 
increased lymphatic resistance to flow may also contribute to the lymphatic dysfunction 
described in obese and MetSyn patients.  
There have been a significant number of studies that have described the 
expression and activation of eNOS in the blood vasculature in relation to insulin 
resistance and obesity (39, 70, 92, 178). Similar mechanisms have yet to be described for 
the lymphatic endothelium and many questions remain to fully explain the lymphatic 
thoracic duct impairment in MetSyn rats. Intriguingly, treatment of normal thoracic 
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ducts with LNAME induces a flow-mediated inhibition of contractility response similar 
to that observed in the MetSyn thoracic duct. However, MetSyn thoracic ducts had an 
even greater exacerbation of poor flow-mediated inhibition of contractility when treated 
with LNAME. This suggests that the MetSyn lymphatic thoracic duct phenotype is 
unlikely to be due to just eNOS expression abrogation. There have been recent studies 
that have observed a significant role of adipose-derived relaxation factors that are 
reduced in adipose dysfunction (110). Additionally, the adipose tissue is also a source of 
contraction stimulating factors in obesity, yet their role on the lymphatics is unknown 
(210, 240). We hypothesize that reduced NO production, increased NO sensitivity, and 
activation of the thoracic duct pacemaker cells combine to drive the MetSyn thoracic 
duct phenotype.  
 
Limitations 
The mouse myeloid system has been critically described and cell populations 
distinguished by specific combinations of proteins markers. The expression of these 
markers and specificity for similar cell types in the human and rat have been questioned. 
Additionally, advances in the production or reliable and specific antibodies against rat 
proteins is lacking compared to antibodies to the same proteins in humans and mice. 
This has hampered the ability to clearly identify immune cell populations and especially 
macrophage polarizations, which fall on a spectrum of activation in the tissue rather than 
specific polarizations (219). We utilized immunohistochemistry to identify rat 
macrophages using antibodies that have been well validated in the rat. Current studies in 
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the rat commonly utilize the expression of MHCII, CD163, and CD206 in the 
identification of rat macrophages and use in the identification of M1 and M2 “skewness” 
(334, 335). However, extensive characterization of specific macrophage phenotypes 
requires a more detailed understanding of rat macrophage heterogeneity and 
identification of potential specific markers. In addition to the reliability of specific 
antibodies and known markers, the mouse model also has the advantage of genetic 
manipulation that can allow perturbations of gene expression or entire cell populations. 
Use of intra-vital microscopy of fluorescently labeled macrophage populations will also 
increase our understanding of dynamic macrophage behavior and flux along the 
lymphatic vessels.  
We chose to use the rat model due to its similarity in the lymphatic contractility 
as human lymphatic vessels to appropriately assess the role of inflammation, 
macrophage phenotype, and lymphatic contractility. The mouse has only a few 
lymphatic beds that display consistent and functional lymphatic contractility and may 
not lend itself to being as strong a model for the lymphatic impairment in MetSyn. 
However, mouse models provide powerful tools that may provide key insight into the 
role of different macrophage populations and interaction with the lymphatic vasculature. 
The strength of this work lies in the direct control and isolation of a specific 
lymphangion through isobaric preparations. This provides unique evidence for 
dysfunction of the lymphatic pump and an argument for the inclusion of macrophages in 
the regulation of lymphatic collecting vessel function. In situ observations of lymphatic 
functions will also provide significant information detailing lymphatic contractility 
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dysfunction in the tissue and how this relates to the maintenance of tissue homeostasis 
by macromolecule clearance. Additionally, differences in observation between both 
isobaric and in situ studies will provide evidence for the role of the lymphatic 
microenvironment and lymph contents in the paracrine regulation of lymphatic function.  
There is also a significant lag in the research on endothelial dysfunction and the 
role of insulin in the lymphatic endothelial cell regulation and specifically in species and 
tissue-specific endothelial cell cultures. Gender- and tissue-specific cell culture lines of 
different regional lymphatic tissues are needed to further and completely characterize the 
lymphatic endothelial response to insulin. Additionally, characterization of the lymph 
composition, including glucose, fatty acids, insulin, and inflammatory cytokines, will be 
crucial to delineating the mechanisms by which eNOS expression is reduced in MetSyn 
thoracic ducts. There is a significant overlap in the symptoms of the MetSyn and 
lymphatic dysfunction and more research needs to be targeted to this connection for 
proper health care of a growing population at risk for lymphedema. 
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APPENDIX 
 
APSS   Albumin Physiological Saline Solution 
CCL1 Chemokine Ligand 1 
CCL2 Monocyte Chemoattractant Protein 1 
CVD Cardiovascular Disease 
eNOS Endothelial NOS 
GMCSF Granulocyte / Monocyte Colony Stimulating Factor 
i.p Intra-peritoneal 
IL-6 Interleukin 6 
iNOS Inducible NOS 
KATP ATP Sensitive Potassium Channels 
LNAME L-NG-Nitro Arginine Methyl Ester 
LPS Lipopolysaccharide 
MCSF Monocyte Colony Stimulating Factor 
MetSyn Metabolic Syndrome 
MHCII Major Histocompatibility Complex II 
MLL Massive Localized Lymphedema 
MLV Mesenteric Lymphatic Vessel 
NO Nitric Oxide 
PSS Physiological Saline Solution 
QPCR Quantitative Polymerase Chain Reaction 
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SNAP S-Nitro-N-Acetylpenicillamine 
TGFβ Transforming Growth Factor β 
TIIDM Type II Diabetes Mellitus 
TNFα Tumor Necrosis Factor α 
 
 
 
